CN113402520A - WEE1 protein degradation agent - Google Patents

WEE1 protein degradation agent Download PDF

Info

Publication number
CN113402520A
CN113402520A CN202010181416.3A CN202010181416A CN113402520A CN 113402520 A CN113402520 A CN 113402520A CN 202010181416 A CN202010181416 A CN 202010181416A CN 113402520 A CN113402520 A CN 113402520A
Authority
CN
China
Prior art keywords
group
compound
formula
subscript
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010181416.3A
Other languages
Chinese (zh)
Inventor
李佳
吕伟
肖栋槐
周宇波
刘婕妤
胡小蓓
王培培
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN202010181416.3A priority Critical patent/CN113402520A/en
Publication of CN113402520A publication Critical patent/CN113402520A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

The invention provides WEE1 protein degradation agents. Specifically, the invention provides a compound shown as a formula V, or pharmaceutically acceptable salt thereof, or stereoisomer thereof, Y-L-MWEE1(V) wherein MWEE1Is a WEE1 binding moiety capable of binding to WEE1 protein kinase; y is an E3 ubiquitin ligase ligand moiety; and L is a linking group.

Description

WEE1 protein degradation agent
Technical Field
The invention belongs to the field of chemistry. In particular to a WEE1 protein degradation agent.
Background
Uncontrolled proliferation of tumor cells is a basic biological characteristic of malignant tumors, and relates to cell cycle regulation mechanism and cell conduction pathway change of DNA damage repair. The WEE1 protein is a cell cycle regulatory protein, is one of important members of a serine/threonine protein kinase family, and affects the combination of the WEE1 protein and CyclinB to block the transition from the G2 phase to the M phase by regulating the phosphorylation state of CDK1, thereby ensuring the DNA replication accuracy and the chromatin integrity. Thus, the WEE1 protein is a key protein kinase involved in the cell cycle G2/M checkpoint and DNA damage repair process. On the other hand, in normal cell cycle progression, the p53 protein can also monitor genome integrity by regulating the G1/S phase and DNA damage check, but most tumor cells have a deletion of the p53 gene, resulting in a defective G1/S checkpoint in their cell cycle. Therefore, the p 53-deleted tumor cells are more dependent on the G2/M checkpoint in the process of DNA replication and damage repair, so that WEE1 protein kinase is highly expressed. Theoretically, by inhibiting the activity of WEE1 protein kinase, the DNA damage of these p 53-deleted tumor cells cannot be repaired in time and enter M phase, causing genomic instability and chromosome deletion, triggering mitotic catastrophe, leading to tumor cell apoptosis. Although AZD1775 has made some clinical research progress as a WEE1 protein target inhibitor, there still exist some application limitations including significant clinical toxic side effects such as nausea, fatigue, thrombocytopenia, and insufficient targeting, for example, AZD1775 has been shown to have PLK1/WEE1 dual target inhibition.
Figure BDA0002412646800000011
In view of the above, there is an urgent need in the art to develop a new drug targeting the WEE1 protein with high selectivity.
Disclosure of Invention
The invention aims to provide a WEE1 protein degrading agent with high selectivity and excellent anti-tumor proliferation activity.
In a first aspect of the invention, there is provided a compound of formula V, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof;
Y-L-MWEE1 (V)
wherein the content of the first and second substances,
MWEE1is a WEE1 binding moiety capable of binding to WEE1 protein kinase;
y is an E3 ubiquitin ligase ligand moiety; and
l is a linking group.
In another preferred embodiment, the E3 ubiquitin ligase ligand moiety is capable of binding to CRBN or CRL4CRBNAnd (4) combining.
In another preferred example, the E3 ubiquitin ligase ligand is CRBN ligand or CRL4CRBNE3 ubiquitin ligase ligand.
In another preferred embodiment, Y is a group represented by formula A;
Figure BDA0002412646800000021
wherein the content of the first and second substances,
z is selected from the group consisting of: c (═ O), C (R)a)2、N(Rb)；
V1、V2、V3And V4One is C and the others are each independently selected from the group consisting of: c (R)a) And N;
R3selected from the group consisting of: H. halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl;
Raeach independently selected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
Rbeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p1 is 0, 1, 2, or 3.
In another preferred embodiment, RaIs H.
In another preferred embodiment, R3Is H.
In another preferred embodiment, Z is C (═ O) or C (R)a)2(ii) a Preferably, Z is C (═ O) or CH2。
In another preferred embodiment, V1、V2、V3And V4One is C and the others are CH.
In another preferred embodiment, V1Is C and V2、V3And V4Are all CH; or, V2Is C and V1、V3And V4Are all CH; or, V3Is C and V1、V2And V4Are all CH; or, V4Is C and V1、V2And V3Are both CH.
In another preferred example, subscript p1 ═ 0.
In another preferred embodiment, Z, V1、V2、V3、V4、R3、RdAnd p1 are each independently the corresponding group in the specific compound in table 1.
In another preferred embodiment, Y is a group as shown in formula a1, a2, A3 or a 4;
Figure BDA0002412646800000022
in the formulae (III), (III) Z, R3As defined above.
In another preferred embodiment, Y is a group as shown in formula A1.
In another preferred embodiment, Y is a group as shown in formula A1, and wherein R is3H and/or Z is C (═ O). .
In another preferred embodiment, Y is a group represented by formula B;
Figure BDA0002412646800000023
wherein the content of the first and second substances,
V1、V2、V3and V4One is C and the others are each independently selected from the group consisting of: c (R)a) And N;
V5and V7Each independently selected from the group consisting of: c (R)a) And N;
V6selected from the group consisting of: c (R)6) And N;
R6selected from the group consisting of: H. cyano, C1-C6 alkyl (preferably, C1-C4 alkyl), C1-C6 haloalkyl;
Raeach independently selected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p1 ═ 0, 1, 2, or 3.
In another preferred embodiment, V1、V2、V3And V4One is C and the others are CH.
In another preferred embodiment, V1Is C and V2、V3And V4Are all CH; or, V2Is C and V1、V3And V4Are all CH; or, V3Is C and V1、V2And V4Are all CH; or, V4Is C and V1、V2And V3Are both CH.
In another preferred embodiment, V5And V7Are all N.
In another preferred embodiment, V6Is C (R)6) And R is6Is C1-C6 alkyl (preferably, C1-C4 alkyl); preferably, V6Is C (CH)3)。
In another preferred example, subscript p1 ═ 0.
In another preferred embodiment, V1、V2、V3、V4、V5、V6、V7、RdAnd subscript p1 are each independently the corresponding groups in the specific compounds in table 1.
In another preferred embodiment, Y is a group as shown in formula B1;
Figure BDA0002412646800000031
in another preferred embodiment, Y is a group represented by formula C;
Figure BDA0002412646800000032
wherein the content of the first and second substances,
R4selected from the group consisting of: H. halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; and
R5selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl.
In another preferred embodiment, R4Selected from the group consisting of: hydroxyl, C1-C6 alkoxy.
In another preferred embodiment, R5Selected from the group consisting of: H. C1-C6 alkyl (preferably, C1-C4 alkyl; more preferably, methyl).
In another preferred embodiment, R4And R5Each independently is a group corresponding to the particular compound in table 1.
In another preferred embodiment, Y is a group as shown in formula C1 or C2;
Figure BDA0002412646800000033
in the formulae, R4As defined above.
In another preferred embodiment, Y is a group as shown in formula C1.
In another preferred embodiment, Y is a group of formula C1 and R4Is a hydroxyl group.
In another preferred embodiment, L is a linking group as shown in formula D
-(ML)s- (D)；
Wherein the content of the first and second substances,
MLare structural units each independently selected from the group consisting of: -C (R)c)2-、-C(Rc)2-C(Rc)2-O-、-C(Rc)2-C(Rc)2-S-、-O-、-S-、-N(Rn)-、-C(＝O)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn)-、-N(Rn)C(＝O)N(Rn)-、-SO-、-SO2-, -CH ═ CH-, -C ≡ C-, -C3-C8 cycloalkyl-, -4-to 7-membered heterocyclyl-, -C6-C10 aryl-, -5-or 6-membered heteroaryl-; wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are unsubstituted or optionally substituted with one or more (preferably, 1, 2, or 3) substituents selected from the group consisting of: halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl;
subscript s is an integer of 1-30; preferably, the subscript s is an integer of 3 to 25; more preferably, the subscript s is an integer of 3 to 20;
Rceach independently selected from the group consisting of: H. hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C3-C5 cycloalkyl; and
Rneach independently selected from the group consisting of: H. C1-C4 alkyl, C1-C4 haloalkyl, C3-C5 cycloalkyl.
In another preferred embodiment, subscript s is 3,4, 5, 6, 8, 9, 10, 11, 12, 13, 14, or 15.
In another preferred embodiment, RcIs H.
In another preferred embodiment, RnIs H.
In another preferred embodiment, L is a linking group according to formula D1:
-Q1-(C(Rc)2)n-W-(C(Rc)2)n-W-(C(Rc)2)m- (D1)
wherein the content of the first and second substances,
Q1selected from the group consisting of: none (absent), -O-, -S-, -CH ═ CH-, -C ≡ C-, -N (R ≡ C)n)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn) -and-N (R)n)C(＝O)N(Rn)-；
Each W is independently selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Each subscript n is independently 0, 1, 2, 3,4, 5, 6, 7, or 8;
subscript m is 0, 1, 2, 3,4, 5, or 6;
Rcand RnAs defined in formula D.
In another preferred embodiment, subscript m and each n are not simultaneously 0.
In another preferred embodiment, Q1Is linked to Y.
In another preferred embodiment, Q1Selected from the group consisting of: none (absent), -O-, -CH-, -C.ident.C-, -NH-, -NHC (. ident.O) -and-NHC (. ident.O) NH-.
In another preferred embodiment, each W is independently selected from the group consisting of: none, -NHC (═ O) -, -C (═ O) NH-.
In another preferred embodiment, L is a linking group according to formula D1 a:
-Q1-(CH2)n-W-(CH2)n-W-(CH2)m- (D1a)
wherein Q is1Subscripts m, W, and subscript n are as defined in formula D1.
In another preferred embodiment, Q1、Rn、RcW, subscript m, and subscript n are each independently the corresponding groups in the specific compounds in table 1.
In another preferred embodiment, L is a linking group according to formula D2:
-Q2-[C(Rc)2-C(Rc)2-O]v-(C(Rc)2)o-W-(C(Rc)2)m- (D2)
wherein the content of the first and second substances,
Q2selected from the group consisting of: -N (R)n)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn) -and-N (R)n)C(＝O)N(Rn)-；
W is selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Subscript v is 0, 1, 2, 3,4, 5, 6, 7, 8, 9, or 10;
subscript m is 0, 1, 2, 3,4, 5, or 6;
subscript o is 1, 2, or 3;
Rcand RnAs defined in formula D.
In another preferred embodiment, subscript v is 1, 2, 3,4, 5, 6, 7, 8, 9, or 10.
In another preferred embodiment, Q2Is linked to Y.
In another preferred embodiment, Q2Selected from the group consisting of: -NH-, -NHC (═ O) -and-NHC (═ O) NH-.
In another preferred embodiment, W is selected from the group consisting of: none, -NHC (═ O) -, -C (═ O) NH-.
In another preferred embodiment, L is a linking group according to formula D2 a:
-Q2-[CH2-CH2-O]v-(CH2)2-W-(CH2)m- (D2a)
wherein Q is2Subscripts v, W and subscript m are as defined in formula D2.
In another preferred embodiment, Q2、Rn、RcW, subscript v, subscript o and subscript m are each independently the corresponding groups in the specific compounds of table 1.
In another preferred embodiment, L is a linking group according to formula D3:
-Q3-(C(Rc)2)r1-Ar1-(C(Rc)2)r2-U-(C(Rc)2)n-W-(C(Rc)2)m- (D3)
wherein the content of the first and second substances,
Q3selected from the group consisting of: -N (R)n) -, -O-and-S-;
Ar1selected from the group consisting of: -C3-C8 cycloalkyl-, 4-to 7-membered heterocyclyl-, -C6-C10 aryl-, -5-or 6-membered heteroaryl-;
w is selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
U is selected from the group consisting of: -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Subscript n is 0, 1, 2, 3,4, 5, 6, 7, or 8;
subscript m is 0, 1, 2, 3,4, 5, or 6;
subscript r1 and subscript r2 are each independently 0, 1, or 2;
Rcand RnAs defined in formula D.
In another preferred embodiment, - (C (R)c)2)r2-U-is-C (═ O) N (R)n) -or- (C (R)c)2)-N(Rn)C(＝O)-。
In another preferred embodiment, - (C (R)c)2)r2-U-is-C (═ O) NH or- (C (R)c)2)-NHC(＝O)-。
In another preferred embodiment, Q3Is linked to Y.
In another preferred embodiment, Q3Selected from the group consisting of: -NH-and-O-.
In another preferred embodiment, Ar1Selected from the group consisting of: -C6-C10 aryl-, -5-or 6-membered heteroaryl-.
In another preferred embodiment, L is a linking group according to formula D3 a:
-Q3-(CH2)-Ph-(CH2)r2-U-(CH2)n-W-(CH2)m- (D3a)
wherein Ph is phenyl, and r2 is 0 or 1; and Q3U, subscript m, W, and subscript n are as defined in formula D3.
In another preferred embodiment, Q3、W、U、Ar1、Rn、RcSubscript r1, subscript r2, subscript m, and subscript n are each independently the corresponding groups of the particular compounds of table 1.
In another preferred embodiment, L is a linking group as shown in formula D1.
In another preferred embodiment, L is a linking group as shown in formula D1 a.
In another preferred embodiment, L is a linking group as shown in formula D1 or D1a, and Q1Is NH.
In another preferred embodiment, L is a linking group as shown in formula D1 or D1a, and W is nothing.
In another preferred embodiment, L is a linking group as shown in formula D1 or D1a, and W are both absent, subscript m is 0, one of subscripts n is 0, and the other subscript n is 1, 2, 3,4, 5, 6, 7, or 8. In another preferred embodiment, L is-NH- (CH)2)n-。
In another preferred embodiment, MWEE1Is a WEE1 binding moiety derived from a WEE1 kinase inhibitor.
In another preferred embodiment, MWEE1Is a WEE1 binding moiety derived from a compound selected from the group consisting of: AZD 1775.
In another preferred embodiment, MWEE1As shown in formula E:
Figure BDA0002412646800000061
wherein the content of the first and second substances,
Cy1selected from the group consisting of: substituted or unsubstituted C6-C10 cycloalkyl, substituted or unsubstituted 5-to 10-membered heterocycloalkyl (preferably, 5-or 6-membered heterocycloalkyl);
Cy2selected from the group consisting of: substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl (preferably, 5-or 6-membered heteroaryl);
Rbeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. halogen, C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p2 is 0, 1, 2, or 3;
R1selected from the group consisting of: substituted or unsubstituted C1-C6 alkyl (preferably, C1-C4 alkyl), substituted or unsubstituted C1-C6 alkenyl (preferably, C1-C4 alkenyl), substituted or unsubstituted C1-C6 alkynyl (preferably, C1-C4 alkynyl), substituted or unsubstituted benzyl;
R2selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl (preferably, C1-C4 alkyl), substituted or unsubstituted C1-C6 alkoxy (preferably,C1-C4 alkoxy), substituted or unsubstituted C6-C10 aryl;
x is selected from the group consisting of: c (R)a) And N;
Raselected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
unless otherwise specified, said substitution means that one or more (preferably, 1, 2, 3,4 or 5) hydrogens on the group are substituted with a substituent selected from the group consisting of: hydroxyl, halogen (preferably, F, Cl, Br), CN, C1-C6 alkyl, C1-C6 haloalkyl.
In another preferred embodiment, X is N.
In another preferred embodiment, subscript p2 is 0.
In another preferred embodiment, Cy2Is a C6-C10 aryl group; preferably, it is phenyl.
In another preferred embodiment, Cy1Is a 5 to 10 membered heterocycloalkyl group containing at least one N heteroatom.
In another preferred embodiment, Cy1Is composed of
Figure BDA0002412646800000062
Wherein, and Cy2And (4) connecting.
In another preferred embodiment, R1Is substituted or unsubstituted C1-C6 alkenyl; preferably, it is a substituted or unsubstituted C1-C4 alkenyl group; more preferably, R1Selected from: -CH2CH＝CH2、-CH2CH2CH＝CH2、-CH(CH3)CH＝CH2、-CH2CH＝CH(CH3)、-CH2CH＝C(CH3)2。
In another preferred embodiment, R2Selected from the group consisting of: H. halogen, C1-C4 alkyl (preferably methyl), C1-C4 alkoxy (preferably methoxy), C1-C4 haloalkyl (preferably trifluoromethyl), hydroxy-substituted C1-C4 alkyl (preferably-C (CH)3)2OH), substituted or unsubstituted phenyl.
In another preferred embodiment, Cy1、Cy2、R1、R2、Rb、RdX, and subscript p2 are each independently the corresponding groups in the specific compounds in table 1.
In another preferred embodiment, MWEE1Is a group represented by E1;
Figure BDA0002412646800000071
in a second aspect of the invention, there is provided a compound of formula I;
Figure BDA0002412646800000072
wherein R is1、R2Y and L are as defined for formula V.
In another preferred embodiment, Y is a group represented by formula A; preferably, Y is a group as shown in formula A1.
In another preferred embodiment, Y is a group as shown in formula A1, and wherein R is3H and/or Z is C (═ O).
In another preferred embodiment, when Y is a group of formula A or formula A1, L is a linking group of formula D1; preferably, it is a linking group as shown in formula D1 a.
In another preferred embodiment, when Y is a group of formula A or formula A1, L is a linking group of formula D1a, and Q is in formula D1a1is-NH-, further in formula D1a where W is all absent, further in formula D1a where m is 0, one of n is 0, and the other n is 1, 2, 3,4, 5, 6, 7 or 8.
In another preferred embodiment, when Y is a group of formula A or formula A1, L is-NH- (CH)2)n-。
In another preferred embodiment, the compound is represented by formula III;
Figure BDA0002412646800000073
wherein n is 1, 2, 3,4, 5, 6, 7 or 8.
In another preferred embodiment, Y is a group represented by formula C; preferably, Y is a group as shown in formula C1.
In another preferred embodiment, Y is a group of formula C1, and wherein R4Is a hydroxyl group.
In another preferred embodiment, when Y is a group of formula C or formula C1, L is a linking group of formula D1; preferably, it is a linking group as shown in formula D1 a.
In another preferred embodiment, when Y is a group of formula C or formula C1, L is a linking group of formula D1a, and Q is in formula D1a1is-NHC (═ O) -, further in formula D1a W is absent, further in formula D1a m is 0.
In another preferred embodiment, when Y is a group of formula C or formula C1, L is-NHC (═ O) - (CH)2)n-。
In another preferred embodiment, the compound is represented by formula IV;
Figure BDA0002412646800000081
wherein n is 1, 2, 3,4, 5, 6, 7 or 8.
In another preferred embodiment, Y is a group of formula A (preferably, a group of formula A1) and L is a linking group of formula D1 (preferably, a linking group of formula D1 a).
In another preferred embodiment, the compound is selected from the compounds in table 1.
In another preferred embodiment, the compound is selected from the group consisting of compounds 1-22 and compounds 25-48 of Table 1; preferably, selected from compounds 1-18 and compounds 25-28 in Table 1; more preferably, it is selected from compounds 1-3 of Table 1.
In another preferred embodiment, the compound is compound 2 in table 1;
Figure BDA0002412646800000082
in a third aspect of the invention, there is provided a composition comprising (i) a compound as described in the first or second aspect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; and (ii) a pharmaceutically acceptable carrier.
In a fourth aspect of the invention, there is provided the use of a compound according to the first or second aspects, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a composition according to the third aspect, in the manufacture of a medicament for the treatment and/or prevention of a disease or condition mediated by the WEE1 protein.
In another preferred embodiment, the disease or disorder mediated by WEE1 protein is cancer.
In another preferred embodiment, the disease or condition mediated by WEE1 protein is selected from the group consisting of: lymphoma, osteosarcoma, neuroblastoma, glioblastoma, melanoma, ovarian cancer, head and neck cancer, colorectal cancer, pancreatic cancer, liver cancer, skin cancer, lung cancer, kidney cancer, breast cancer, leukemia.
In a fifth aspect of the invention, there is provided a method of treating or preventing a disease or condition mediated by WEE1 protein, comprising the steps of: administering to a subject in need thereof a safe and effective amount of a compound according to the first or second aspect, or a composition according to the third aspect.
In another preferred embodiment, the subject is a mammal, preferably a human.
In a sixth aspect of the invention, a method of degrading WEE1 protein, comprising the steps of: contacting a subject with a compound according to the first or second aspect, thereby degrading WEE1 protein.
In another preferred embodiment, the method is non-therapeutic in vitro.
In another preferred embodiment, the subject is a cell line.
In another preferred embodiment, the subject is a MV-4-11 cell line.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.
Drawings
FIG. 1 shows compounds 1-24 in IC50Immunoblot experiments of concentration-induced WEE1 protein degradation on MV-4-11 tumor cell lines are shown.
FIG. 2 is a graphical representation of the immunoblot experiment of Compound 2 at different concentration gradients on MV-4-11 tumor cell lines inducing WEE1 protein degradation.
FIG. 3 is a graphical representation of the immunoblot experiment of Compound 2 acting on MV-4-11 tumor cell lines at different time gradients to induce WEE1 protein degradation.
Figure 4 is a graphical representation of an immunoblot experiment demonstrating that compound 2 induces WEE1 protein degradation by protein competition binding, relying on the formation of a "WEE 1 protein-compound 2-CRBN protein" ternary complex.
Figure 5 is a bar graph of compound 2 inducing degradation of WEE1 protein but not of WEE 1-expressing mRNA.
FIG. 6 is a bar graph of Compound 2 inducing MV-4-11 tumor cell line cycle arrest.
FIG. 7 is a bar graph of Compound 2 inducing apoptosis of MV-4-11 tumor cell lines.
Detailed Description
The inventors have conducted extensive and intensive studies. Surprisingly, the novel compound formed by connecting the WEE1 target drug with the E3 ligase ligand (especially with the E3 ligase ligand part shown in the formula A) through the connecting group (L) is found to overcome the defect of insufficient targeting selectivity of the existing WEE1 target drug (such as a WEE1 protein kinase inhibitor). In addition, the compound of the invention can effectively degrade WEE1 protein and has excellent anti-tumor proliferation activity. Based on this, the inventors have completed the present invention.
Term(s) for
Unless otherwise stated, the term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom. Further, terms such as "haloalkyl" are meant to include monohaloalkyl or polyhaloalkyl. For example, the term "C1-C6 haloalkyl" or "C1-C4 haloalkyl" includes, for example, trifluoromethyl, 2,2, 2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
As used herein, "C1-C6 alkyl" refers to a straight or branched chain alkyl group including 1-6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, or the like. Similarly, C1-C4 alkyl refers to straight or branched chain alkyl groups including 1-4 carbon atoms.
As used herein, "C1-C6 alkoxy" includes straight or branched chain alkoxy groups of 1-6 carbon atoms. Such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, or the like.
As used herein, "cycloalkyl" refers to a saturated cyclic hydrocarbon group (including monocyclic, bicyclic, such as fused, etc.) containing the indicated number of carbon atoms, for example, "C3-C6 cycloalkyl" refers to a cycloalkyl group containing 3-6 carbon atoms, and "C6-C10 cycloalkyl" includes, examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. Similarly, as used herein, the term "heterocycloalkyl" refers to a group formed by replacement of one or more (e.g., 1, 2, 3, or 4) carbon atoms in a ring in a cycloalkyl group with a heteroatom (e.g., O, S or N).
The term "alkenyl" refers to an unsaturated alkyl group having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds. Examples of unsaturated alkyl groups include: ethenyl, 2-propenyl, ethynyl, 1-and 3-propynyl, 3-butynyl and higher homologs and isomers.
The term "alkylene" by itself or as part of another substituent refers to a divalent radical derived from an alkane, e.g., -CH2CH2CH2CH2-. Unless otherwise defined, alkyl (or alkylene) groups typically have 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein.
Unless otherwise defined, the term "aryl" denotes a polyunsaturated (usually aromatic) hydrocarbon group which may be a single ring or multiple rings (up to three rings, preferably bi-or mono-rings) fused together or covalently linked. The term "heteroaryl" refers to an aryl (or ring) containing 1 to 5 heteroatoms (e.g., selected from N, O, and S), wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom is optionally quaternized. The heteroaryl group may be attached to the rest of the molecule through a heteroatom. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl groups, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuranyl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridyl, thienopyrimidyl, pyrazolopyrimidinyl, imidazopyridine, benzothiazolyl, benzofuranyl, benzothienyl, indolyl, quinolinyl, isoquinolinyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furanyl, thienyl, and the like. Unless otherwise defined herein, "aryl" or "heteroaryl" can also be optionally substituted by a substituent selected from the group consisting of: halogen, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl.
As used herein, the term "heteroatom" is intended to include oxygen (O), nitrogen (N), sulfur (S), and silicon (Si); preferably O, N and S are included.
For the compounds provided herein, a bond from a substituent (typically an R group) to the center of an aromatic ring (e.g., benzene, pyridine, etc.) or cycloalkyl, etc., will be understood to refer to a bond that provides attachment at any available vertex of the aromatic or alkyl ring.
Targeted protein degradation chimera technology (PROTACs)
The target protein degradation chimeras technology (PROTACs) induces protein degradation in a targeted way through the ubiquitination-proteasome approach, initiates a new treatment mode, and becomes a hot field for new drug development in recent years. The PROTACs molecules are bifunctional small molecules formed by connecting a target protein ligand and an E3 ubiquitin ligase ligand through a Linker, and can be simultaneously combined with a target protein and E3 ubiquitin ligase to enable the target protein and the E3 ubiquitin ligase to be close to each other and marked by ubiquitination, so that the target protein and the E3526 ubiquitin ligase are recognized and degraded by proteasomes in cells.
WEE1 protein kinase degradation agent
The existing therapeutic drugs for WEE1 target are small molecule kinase inhibitors, which can inhibit the function of WEE1 protein by occupying the active site of WEE1 protein (or WEE1 protein kinase) to achieve the purpose of treating diseases, and different from the above, the compound of formula I provided by the invention is a WEE1 protein degradation agent, and develops a new therapeutic mode for WEE1 target diseases based on the degradation mechanism of ubiquitination-proteasome pathway. In addition, the compound of the formula I not only has excellent degradation capability of WEE1 protein, but also can selectively degrade WEE1 protein, and does not degrade other proteins such as PLK protein, so that the application limit of insufficient targeting of the existing WEE1 protein kinase inhibitor is overcome, and clinical toxic and side effects caused by the action of the WEE1 protein kinase inhibitor AZD1775 on PLK protein are overcome.
Typically, the invention provides a WEE1 protein degradation agent, as shown in formula V
Y-L-MWEE1 (V)
Wherein M isWEE1Y and L are as defined in the first aspect.
In one embodiment, the invention provides a class of WEE1 protein degrading agents, represented by formula I:
Figure BDA0002412646800000111
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the content of the first and second substances,
R1selected from: substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkenyl, substituted or unsubstituted C2-C4 alkynyl, substituted or unsubstituted benzyl;
R2selected from: hydrogen, halogen (F, Cl, Br, I), C1-C4 alkyl(s) (I)Such as methyl), C1-C4 alkoxy (such as methoxy), C1-C4 haloalkyl (such as trifluoromethyl), hydroxy-substituted C1-C4 alkyl (such as tert-butanol (-C (CH)3)2OH)), a substituted or unsubstituted phenyl group;
y is selected from:
Figure BDA0002412646800000112
wherein Z is selected from: -CH2-and-C (═ O) -; r3Selected from: hydrogen, halogen, methyl and hydroxy; r4Selected from: hydrogen, halogen, methyl and hydroxy;
l is a linking group selected from the group consisting of;
-Q1-(CH2)n-W-(CH2)n-W-(CH2)m-；
-Q2-[CH2-CH2-O]v-(CH2)2-W-(CH2)m-；
-Q3-(CH2)-Ph-(CH2)r2-U-(CH2)n-W-(CH2)m-；
wherein the content of the first and second substances,
Q1selected from: -O-, C2 alkenyl (-CH ═ CH-), C2 alkynyl (-C ≡ C-), -NH-, -NHC (═ O) -, and-NHC (═ O) -NH-, or Q1Is absent;
Q2selected from: -O-, -NH-, -NHC (═ O) -, and-NHC (═ O) NH-;
Q3selected from: -O-and-NH-;
w (each independently) is selected from: -NHC (═ O) -and-C (═ O) NH-, or W is absent;
u is selected from: -C (═ O) NH-and-NHC (═ O) -; and r2 is 0 or 1; n is 0, 1, 2, 3,4, 5, 6, 7 or 8; m is 0, 1, 2, 3,4, 5 or 6; v is 1, 2, 3,4, 5, 6, 7, 8, 9 or 10.
In one embodiment, the compound is of formula II:
Figure BDA0002412646800000121
in one embodiment, Y is
Figure BDA0002412646800000122
Preferably, R3Is hydrogen. Preferably, Z is-C (═ O) -.
Preferably, L is-Q1-(CH2)n-W-(CH2)n-W-(CH2)m-. Preferably, Q1is-NH-. Preferably, W is absent. Preferably, one of n is 0 and m is 0.
Preferably, the compound is of formula III:
Figure BDA0002412646800000123
preferably, the compound of formula III has the following structural formula:
Figure BDA0002412646800000124
in another embodiment, Y is
Figure BDA0002412646800000131
Preferably, R4Is a hydroxyl group.
Preferably, L is-Q1-(CH2)n-W-(CH2)n-W-(CH2)m-. Preferably, Q1is-NH-C (═ O) -. Preferably, W is absent. Preferably, one of n is 0 and m is 0.
Preferably, the compound has formula IV:
Figure BDA0002412646800000132
preferably, the compound of formula IV has the following structural formula:
Figure BDA0002412646800000133
in another embodiment, examples of compounds of the present invention include, but are not limited to, any one or more of the compounds listed in table 1:
TABLE 1
Figure BDA0002412646800000134
Figure BDA0002412646800000141
Figure BDA0002412646800000151
Figure BDA0002412646800000161
Figure BDA0002412646800000171
Figure BDA0002412646800000181
Figure BDA0002412646800000191
Figure BDA0002412646800000201
Figure BDA0002412646800000211
Figure BDA0002412646800000221
Active ingredient
As used herein, the terms "compound of the invention" or "degradant of the invention" or "WEE 1 protein degradant" are used interchangeably and refer to a compound (or degradant) as shown in formula I. The term also includes various crystalline forms, pharmaceutically acceptable salts or hydrates or solvates of the compounds of formula I.
Wherein the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention with an acid or a base, which is suitable for use as a medicament. Pharmaceutically acceptable salts include inorganic and organic salts. One preferred class of salts is that formed by reacting a compound of the present invention with an acid. Suitable acids for forming the salts include, but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, phosphoric acid, and the like; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenesulfonic acid and the like; and amino acids such as proline, phenylalanine, aspartic acid, glutamic acid, etc. Another preferred class of salts are those of the compounds of the invention with bases, for example alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., magnesium or calcium salts), ammonium salts (e.g., lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, triethanolamine salts, and amine salts formed from morpholine, piperazine, lysine, respectively.
The term "solvate" refers to a complex of a compound of the present invention coordinated to solvent molecules in a specific ratio. "hydrate" refers to a complex formed by the coordination of a compound of the present invention with water.
In addition, the compounds of the present invention also include prodrugs of the compounds of formula I. The term "prodrug" includes a class of compounds which are biologically active or inactive in nature and which, when administered by an appropriate method, undergo a metabolic or chemical reaction in the body to convert the compound to formula I, or a salt or solution of a compound of formula I. The prodrugs include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo, phosphoramide, glucoside, ether, acetal forms of the compounds.
Preparation method
The process for the preparation of the compounds of formula I or formula V according to the invention is described in more detail below, but these particular processes do not constitute any limitation of the invention. The compounds of the present invention may also be conveniently prepared by optionally combining various synthetic methods described in the present specification or known in the art, and such combinations may be readily carried out by those skilled in the art to which the present invention pertains. In general, in the preparative schemes, each reaction is usually carried out in an inert solvent at a temperature ranging from room temperature to reflux temperature (e.g., from 0 ℃ to 200 ℃, preferably from 0 ℃ to 120 ℃). The reaction time is usually 0.1 to 60 hours, preferably 0.5 to 48 hours. In general, the process for the synthesis of the compounds represented by the first or second aspect of the invention comprises 2 main steps, namely: step (i) ligation of the Y fragment and the L fragment to give the Y-L fragment, or the L fragment and Mwee1Ligation of fragments to give L-MweeFragment, or Y fragment and L1 fragment and L2 fragment and Mwee1Ligation of the fragments to give Y-L1 fragment and L2-M, respectivelywee1Fragments, and step (ii) Y-L fragments and Mwee1Ligation of fragments, or Y fragment and L-Mwee1Ligation of fragments, or Y-L1 fragment and L2-Mwee1Ligation of fragments; wherein Y fragment is L fragment or L-Mwee1The fragments are capable of forming an E3 ubiquitin junction as described in the first aspectA compound of an enzyme ligand moiety (Y-); l is a group which is linked to the Y fragment and Mwee1The fragments are reacted to form a compound having a linking group (-L-) as described in the first aspect, with fragment L1 and fragment L2 referring to fragments Y and M, respectivelywee1After reaction of the fragments and coupling of the fragments to each other, a compound, M, which together form a linking group (-L-) as described in the first aspectwee1Fragment means that upon reaction with the L fragment or the Y-L fragment, a binding moiety (-M) capable of forming WEE1 as described in the first aspectWEE1) The compound of (1). Each fragment may be modified or unmodified, and may be protected with a protecting group (e.g., Boc) or unprotected. For example,
the Y segment can be
Figure BDA0002412646800000231
Mwee1The fragment can be
Figure BDA0002412646800000232
L, L1 and L2 fragment may each independently be
Figure BDA0002412646800000233
BocNH-(CH2)2-(OCH2CH2)v-NH2、
Figure BDA0002412646800000234
BocNH-(CH2)n-COOH、
Figure BDA0002412646800000235
Br-(CH2)n-COOH; wherein n and v are as defined above.
These fragments, after deprotection (e.g. deprotection by conventional methods or methods described in the specification) and/or modification or replacement of the active group, may be coupled to the remaining fragments according to methods described in the specification or other conventional methods to give compounds according to the first or second aspect.
Pharmaceutical compositions and methods of administration
Because the compound has excellent selective WEE1 protein degradation activity, the compound and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and a pharmaceutical composition containing the compound as a main active ingredient can be used for treating, preventing and relieving diseases mediated by WEE1 protein. According to the prior art, the compounds of the invention are useful for the treatment of the following diseases: cancer, and the like, particularly, for example: lymphoma, osteosarcoma, neuroblastoma, glioblastoma, melanoma, ovarian cancer, head and neck cancer, colorectal cancer, pancreatic cancer, liver cancer, skin cancer, lung cancer, kidney cancer, breast cancer, leukemia.
The pharmaceutical composition of the present invention comprises the compound of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount range and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-500mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.
As used herein, the term "pharmaceutically acceptable" ingredient refers to a substance that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), i.e., at a reasonable benefit/risk ratio.
"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), and the like
Figure BDA0002412646800000241
) Wetting agents (e.g., sodium lauryl sulfate), coloring agents, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.
In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms for topical administration of the compounds of the present invention include ointments, powders, patches, sprays, and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 20 to 500 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.
The main advantages of the invention include
(a) The selectivity is good, and the compound of the invention has no degradation effect on PLK protein.
(b) Has excellent antitumor proliferation effect. Preferred compounds of the invention even have an anti-tumor proliferative capacity superior to the positive control dual-target inhibition of AZD 1775.
(c) The compound of the present invention has excellent degradability of WEE1 protein.
(d) The compound of the invention can effectively induce tumor cell apoptosis.
In general, the WEE1 protein degradation agent (the compound shown in the formula I) provided by the invention can selectively degrade WEE1 protein without degrading PLK protein, has better target selectivity compared with the existing WEE1 kinase inhibitor such as AZD1775(PLK1/WEE1 double-target inhibition effect), and avoids clinical toxic and side effects caused by off-target effect. On the other hand, the WEE1 protein degradation agent based on the PROTAC technology has a catalytic effect, so that the protein degradation agent has the potential advantages of low dosage administration and long drug effect in clinical treatment.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are percentages and parts by weight.
Unless otherwise specified, the starting materials or reagents used in the examples are commercially available.
Example 1: synthetic route of intermediate S15
Step 1: synthesis of Compound S3
Figure BDA0002412646800000251
Compound S1(10.0g,67.5mmol) and compound S2(9.40g,70.9mmol) were added to 110mL of a toluene solution, and the reaction mixtureThe reaction was carried out for 18 hours while the temperature was increased to reflux. After completion of the detection reaction, it was cooled to room temperature, filtered, washed with n-hexane, and the white solid product was collected and spin-dried to give compound S3(16.1g, 91% yield).1H NMR(400MHz,DMSO)δ9.87(s,1H),7.95(d,J＝3.2Hz,4H),1.45(s,9H)。
Step 2: synthesis of Compound S5
Figure BDA0002412646800000252
Compound S3(16.1g,61.2mmol), potassium carbonate (16.1g,116mmol) and benzyltriethylammonium chloride (1.39g,6.12mmol) were added to 110mL of acetonitrile solvent and stirred for 5 minutes, and then compound S4(8mL,91.8mmol) was added to the reaction system and reacted at room temperature for 18 hours. After the detection reaction is finished, 100mL of water is added into the system, extraction is carried out for three times by ethyl acetate, organic phases are combined and washed by saturated saline solution, drying is carried out by anhydrous sodium sulfate, filtration is carried out, filtrate is collected and rotary drying is carried out to obtain a yellow oily crude product. Adding the crude product into n-hexane solution, cooling to 5 ℃, and precipitating a solid. Filtration and washing with n-hexane collected the product as a white solid which was spin dried to give compound S5(15.7g, 85% yield).
And step 3: synthesis of Compound S6
Figure BDA0002412646800000261
Methyl hydrazine (3.40mL,64.3mmol) was added to a 100mL solution of compound S5(15.6g,51.5mmol) in tetrahydrofuran under ice-bath, and after the addition, the ice-bath was removed and the reaction was allowed to proceed at room temperature for 18 hours. Filtering, collecting filtrate and spin-drying to obtain oily crude product. The crude product was added to n-hexane and a white solid precipitated, the filtrate was collected by filtration and spin-dried, and the same operation was repeated three times until no solid precipitated, and spin-dried to give product S6(8.47g, 96% yield) as a yellow oily liquid.1H NMR(400MHz,DMSO)δ5.90-5.66(m,1H),5.16-
4.99(m,2H),4.46(s,2H),3.99-3.76(m,2H),1.40(s,9H)。
And 4, step 4: synthesis of Compound S8
Figure BDA0002412646800000262
DIPEA (20.8mL, 120mmol) and the compound S6(8.23g,47.8mmol) were added to a solution of the compound S7(11.1g,47.8mmol) in 100mL of tetrahydrofuran, and the reaction was heated to reflux for 72 hours. After the reaction was completed, the tetrahydrofuran solvent was removed by rotary evaporation under reduced pressure, and 50mL of diethyl ether was added to the system to precipitate a solid. The filtrate was collected by filtration, spin-dried, cooled to 0 deg.C, added with 40mL of TFA, warmed to room temperature for 1 hour, and then warmed to 70 deg.C for 1 hour. After the solvent of the reaction system was removed by spinning under reduced pressure, 50mL of ethanol was added, the mixture was cooled to 0 ℃ and 75mL of 6M sodium hydroxide solution was added at this temperature, and the mixture was allowed to warm to room temperature for 15 minutes. After completion of the reaction, 40mL of concentrated hydrochloric acid was added to the system, and a yellow solid was precipitated. Removing solvent in the system by rotary removal under reduced pressure, adding 100mL of chloroform and 100mL of aqueous solution, extracting and collecting organic phase, washing with saturated saline solution, drying with anhydrous magnesium sulfate, filtering and collecting filtrate, vacuum concentrating to obtain oily crude product, adding the crude product into n-hexane, and separating out yellow solid. Filtration and washing with ethanol and ether, respectively, collected the yellow solid product, which was spin dried to give compound S8(5.44g, 51% yield).1H NMR(400MHz,DMSO)δ12.75(s,1H),8.68(s,1H),5.87(ddd,J＝15.6,10.1,5.0Hz,1H),5.29-4.91(m,2H),4.38(d,J＝4.3Hz,2H),2.53(s,3H)。
And 5: synthesis of Compound S10
Figure BDA0002412646800000263
Compound S8(900mg,4.05mmol), compound S9(1.14g,5.27mmol) and dimethylethylenediamine (1mL) were sequentially added to 10mL of a1, 4-dioxane solution, and after the system was sufficiently dissolved, potassium carbonate (1.12g,8.1mmol) and cuprous iodide (770mg,4.05mmol) were added to the reaction system, and the temperature was raised to 90 ℃ to react for 18 hours. After the reaction is finished, cooling to room temperature, adding 20mL of ammonia water solution, extracting with ethyl acetate for three times, and combiningThe organic phase was washed with brine, dried over anhydrous magnesium sulfate, filtered, and the filtrate was collected and concentrated to give a crude product. The crude product was isolated and purified by silica gel column chromatography to give S10 as a solid compound (1.04g, 72% yield).1H NMR(400MHz,CDCl3)δ8.96(s,1H),7.93(t,J＝7.9Hz,1H),7.78(dd,J＝8.1,0.7Hz,1H),7.42(dd,J＝7.7,0.8Hz,1H),5.71(ddt,J＝16.4,10.2,6.2Hz,1H),5.07(dd,J＝10.2,1.1Hz,1H),4.95(dq,J＝17.0,1.3Hz,1H),4.82(dt,J＝6.2,1.2Hz,2H),3.82(s,1H),2.60(s,3H),1.60(s,6H)。
Step 6: synthesis of Compound S12
Figure BDA0002412646800000271
Compound S10(2.23g,6.24mmol) was added to 60mL of a toluene solution, followed by m-CPBA (1.18g,6.86mmol) and stirred at room temperature for 1 hour, giving a yellow-green solution. DIPEA (5mL) and compound S11(1.9g,6.86mmol) were added to the reaction system and reacted at room temperature for 18 hours. After the reaction is finished, ethyl acetate is added for extraction, an organic phase is collected, saturated sodium bicarbonate and saturated saline are washed sequentially, anhydrous magnesium sulfate is dried, filtration is carried out, a filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S12 as a yellow solid (1.98g, 54% yield).1H NMR(400MHz,DMSO)δ8.84(s,1H),8.10-7.99(m,1H),7.76(d,J＝7.9Hz,1H),7.65-7.56(m,3H),6.96(d,J＝8.8Hz,2H),5.67(dq,J＝10.6,5.9Hz,1H),5.35(s,1H),5.00(d,J＝10.2Hz,1H),4.83(d,J＝17.2Hz,1H),4.69(d,J＝4.9Hz,2H),3.47(s,4H),3.06(s,4H),2.88(s,1H),1.47(s,6H),1.43(s,9H)。
And 7: synthesis of Compound S13
Figure BDA0002412646800000272
Compound S12(1g,1.70mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S13, which was directly used in the next step without further purification.
And 8: synthesis of Compound S14
Figure BDA0002412646800000273
Compound S13(820mg,1.69mmol) and tert-butyl bromoacetate (300uL) were added to a 5mL DMF solution, and after the system was completely dissolved, potassium carbonate (466mg,3.88mmol) was added, and the temperature was raised to 60 ℃ for reaction for 6 hours. After the reaction was completed, 10mL of water was added, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S14(648mg, 64% yield) as a yellow solid.1H NMR(400MHz,DMSO)δ8.83(s,1H),8.06(t,J＝7.3Hz,1H),7.76(d,J＝7.8Hz,1H),7.67-7.50(m,3H),6.93(d,J＝8.9Hz,2H),5.67(ddt,J＝16.3,10.3,6.0Hz,1H),5.34(s,1H),5.00(dd,J＝10.2,0.8Hz,1H),4.83(dd,J＝17.1,1.0Hz,1H),4.69(d,J＝5.3Hz,2H),3.17(s,2H),3.11(s,4H),2.66(s,4H),1.47(s,6H),1.43(s,9H)。
And step 9: synthesis of Compound S15
Figure BDA0002412646800000274
Compound S14(600mg,1mmol) was added to a mixed solvent of 1mL TFA and 2mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S15, which was directly used in the next step without further purification.
Example 2: general synthetic route to Compounds 1-3
Figure BDA0002412646800000281
Synthetic route to compound 1:
step 1: synthesis of Compound S18
Figure BDA0002412646800000282
Compounds S13(250mg,0.51mmol) and S17(148mg,0.62mmol) were added to a 10mL DMF solution, and after the system was completely dissolved, potassium carbonate (141mg,1.02mmol) was added and the reaction was allowed to warm to 60 ℃ for 6 hours. After the reaction was completed, 100mL of water was added, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S18 as a yellow solid (220mg, 67% yield).1H NMR(400MHz,DMSO)δ10.17(s,1H),8.83(d,J＝1.0Hz,1H),8.05(s,1H),7.75(d,J＝7.3Hz,1H),7.65-7.46(m,3H),6.92(d,J＝7.6Hz,2H),6.83(s,1H),5.66(dd,J＝14.5,8.9Hz,1H),5.33(s,1H),4.99(d,J＝10.2Hz,1H),4.82(d,J＝17.1Hz,1H),4.72-4.63(m,2H),3.16-3.02(m,4H),2.94(t,J＝12.5Hz,2H),2.50(s,4H),2.37-2.23(m,2H),1.59(t,J＝12.0Hz,2H),1.46(s,6H),1.38(s,9H)。
Step 2: synthesis of Compound S19
Figure BDA0002412646800000283
Compound S18(150mg,0.23mmol) was added to a mixed solvent of 1mL TFA and 2mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S19, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 1
Figure BDA0002412646800000284
Compounds S16(56mg,0.20mmol) and S19(100mg,0.18mmol) were added to a 3mL DMF solution, DIPEA (70uL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 30mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to give yellow solid Compound 1(98mg, 68% yield)Rate).1H NMR (400MHz, DMSO) δ 11.09(s,1H),10.17(s,1H),8.83(s,1H),8.10-8.00(m,1H),7.75(d, J ═ 7.6Hz,1H),7.70-7.47(m,4H),7.16(d, J ═ 8.4Hz,1H),7.11-6.86(m,3H),6.79(t, J ═ 5.4Hz,1H),5.67(ddd, J ═ 17.1,10.8,5.9Hz,1H),5.34(s,1H),5.09-4.95(m,2H),4.82(d, J ═ 16.9Hz,1H),4.74-4.59(m,2H),3.53-3.34(m, 3.03H), 3.94 (m, 3.01-4H), 3.49 (m,1H), 1H, 3.49 (d, 1H), 3.49H, 1H, and 1H. HRMS (ESI) m/z calculated value C42H45N11O6[M+H]+: 800.3633, found: 800.3650.
synthesis of Compound 2: the concrete steps are as in the synthesis example of the compound 1.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.15(s,1H),8.83(s,1H),8.05(s,1H),7.76(d, J ═ 7.3Hz,1H),7.70-7.49(m,4H),7.14(d, J ═ 8.3Hz,1H),7.03(d, J ═ 6.7Hz,1H),6.92(d, J ═ 8.0Hz,2H),6.59(s,1H),5.67(dd, J ═ 16.5,9.7Hz,1H),5.32(s,1H),5.06(dd, J ═ 12.6,2.9Hz,1H),5.00(d, J ═ 10.1Hz,1H),4.83(d, 17.0 (d, J ═ 3.65), 3.3.65 (d, J ═ 3.0, 3.3H), 3.3.3H, 3.3H, 3.3.3 (d, 3-2H), 3.3H, 3H, 3.65 (d, 3.3H), 3H, 3.3H, 3.3.3.3.0 (d, 3H), 1H) 1.70-1.51(m,4H),1.47(s, 6H). HRMS (ESI) m/z calculated value C43H47N11O6[M+H]+: 814.3789, found: 814.3760.
synthesis of Compound 3: the concrete steps are as in the synthesis example of the compound 1.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.16(s,1H),8.83(s,1H),8.09-7.98(m,1H),7.76(d, J ═ 6.1Hz,1H),7.69-7.47(m,4H),7.11(d, J ═ 8.3Hz,1H),7.03(d, J ═ 6.6Hz,1H),6.91(d, J ═ 7.6Hz,2H),6.55(s,1H),5.67(dd, J ═ 14.7,7.9Hz,1H),5.33(s,1H),5.02(dd, J ═ 22.6,9.4Hz,2H),4.83(d, J ═ 17.0, 1H),4.69(s, 1H), 3.34H), 3.18 (m, 3.55H), 2.55H, 2H, 2.3.55 (m ═ 2H, 3.0, 3.55H, 2H, 1, 2H) 1.55-1.43(m,8H),1.40-1.32(m, 2H). HRMS (ESI) m/z calculated value C44H49N11O6[M+H]+: 828.3946, found: 828.3923.
example 3: general synthetic route to Compounds 4-7
Figure BDA0002412646800000291
Synthetic route for compound 4:
step 1: synthesis of Compound S21
Figure BDA0002412646800000292
Compounds S16(1g,3.62mmol) and S20(630mg,3.62mmol) were added to a 10mL DMF solution, DIPEA (1.5mL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 100mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S21 as a yellow solid (1.17g, 75% yield).1H NMR(400MHz,DMSO)δ11.09(s,1H),7.57(t,J＝7.3Hz,1H),7.08(d,J＝8.4Hz,1H),7.02(d,J＝6.6Hz,1H),6.91(s,1H),6.66(s,1H),5.05(d,J＝9.1Hz,1H),3.29(t,J＝12.3Hz,2H),3.00(d,J＝4.4Hz,2H),2.89(t,J＝15.1Hz,1H),2.64-2.53(m,2H),2.09-1.96(m,1H),1.72-1.59(m,2H),1.38(s,9H)。
Step 2: synthesis of Compound S22
Figure BDA0002412646800000301
Compound S21(200mg,0.47mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S22, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 4
Figure BDA0002412646800000302
Compound S15(163mg,0.30mmol) and compound S22(100mg,0.30mmol) were added to 5mL of DMF and stirredAfter dissolution with stirring, HATU (230mg,0.60mmol) and DIPEA (200uL) were added and the mixture was reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 4 as a yellow solid (156mg, 61% yield).1H NMR (400MHz, DMSO) δ 11.11(s,1H),10.18(s,1H),8.84(s,1H),8.18-7.99(m,2H),7.76(d, J ═ 7.4Hz,1H),7.67-7.48(m,4H),7.10(d, J ═ 8.6Hz,1H),7.03(d, J ═ 6.8Hz,1H),6.94(d, J ═ 8.0Hz,2H),6.75(s,1H),5.67(dd, J ═ 16.4,10.0Hz,1H),5.34(s,1H),5.07(d, J ═ 10.9Hz,1H),5.00(d, J ═ 10.0, 1H),4.83(d, 17.65, 1H),5.07(d, J ═ 2H), 3.73H, 3.0H, 3.73 (m, 3.0H), 3.73 (d, 2H, 3.0H), 3.73 (m, 3.0H, 3.0H), 3.0 (m-2H), 2H) 1.47(s,6H),1.31-1.18(m, 2H). HRMS (ESI) m/z calculated value C44H48N12O7[M+H]+: 857.3847, found: 857.3856.
synthesis of Compound 5: the concrete steps are as in the synthesis example of the compound 4.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.17(s,1H),8.84(s,1H),8.05(s,1H),7.90(s,1H),7.76(d, J ═ 7.0Hz,1H),7.68-7.52(m,4H),7.12(d, J ═ 8.4Hz,1H),7.02(d, J ═ 6.7Hz,1H),6.92(d, J ═ 8.0Hz,2H),6.58(s,1H),5.67(dd, J ═ 15.9,9.5Hz,1H),5.34(s,1H),5.03(dd, J ═ 21.8,10.1, 2H),4.83(d, 17.0, 1H),4.76 (s,1H), 3.6.6.6, 6, 13H, 3.06H, 3.6.6, 6.6, 6, 2H, 6.6, 2H, 4.6.6, 4(dd, 15, 2H), 4.6.6, 3, 3.6.6, 6, 6.6.6, 6, 6.6, 6, 3, 6, 3, 6.6, 2H, 3, 2H, 6, 3, etc. HRMS (ESI) m/z calculated value C45H50N12O7[M+Na]+: 893.3823, found: 893.3845.
synthesis of Compound 6: the concrete steps are as in the synthesis example of the compound 4.1H NMR(400MHz,DMSO)δ11.10(s,1H),10.15(s,1H),8.83(s,1H),8.05(t,J＝6.8Hz,1H),7.85-7.72(m,2H),7.67-7.51(m,4H),7.10(d,J＝8.4Hz,1H),7.02(d,J＝6.8Hz,1H),6.92(d,J＝8.1Hz,2H),6.60-6.48(m,1H),5.67(ddt,J＝16.0,10.7,5.2Hz,1H),5.33(s,1H),5.11-4.93(m,2H),4.84(d,J＝17.2Hz,1H),4.75-4.61(m,2H),3.35-3.27(m,4H),3.22-3.09(m,6H),3.01-2.79(m,3H),2.67-2.55(m,5H),2.07-1.97(m,1H),1.65-155(m,2H),1.47(s,6H),1.40-1.28(m, 2H). HRMS (ESI) m/z calculated value C46H52N12O7[M+Na]+: 907.3980, found: 907.3984.
synthesis of compound 7: the concrete steps are as in the synthesis example of the compound 4.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.16(s,1H),8.84(s,1H),8.05(s,1H),7.86-7.70(m,2H),7.67-7.52(m,4H),7.09(d, J ═ 8.5Hz,1H),7.02(d, J ═ 6.9Hz,1H),6.93(d, J ═ 8.0Hz,2H),6.54(s,1H),5.67(td, J ═ 15.8,5.8Hz,1H),5.33(s,1H),5.10-4.96(m,2H),4.83(d, J ═ 17.1Hz,1H),4.74-4.61(m,2H),3.29(d, 6.5, 2H),3.7 (m,2H), 3.15, 2H), 3.0H, 2H), 3.7.7-7.7 (m,1H), 3.7H), 5.7 (d, 2H), 3.7H, 3.8H), 5.7 (m ═ 2H), 3.7H, 2H), 1.67-1.52(m,2H),1.48-1.24(m, 12H). HRMS (ESI) m/z calculated value C47H54N12O7[M+H]+: 899.4317, found: 899.4307.
example 4: synthetic route to Compound 8
Step 1: synthesis of Compound S24
Figure BDA0002412646800000311
Compounds S16(1g,3.62mmol) and S23(700mg,4.34mmol) were added to a 10mL DMF solution, DIPEA (1.9mL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 100mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S24 as a yellow solid (950mg, 63% yield).1H NMR(400MHz,DMSO)δ11.09(s,1H),7.58(t,J＝7.8Hz,1H),7.14(d,J＝8.6Hz,1H),7.03(d,J＝7.1Hz,2H),6.71(s,1H),5.05(dd,J＝12.9,5.2Hz,1H),3.40-3.34(m,2H),3.12(dd,J＝11.4,5.8Hz,2H),2.96-2.83(m,1H),2.59(d,J＝17.4Hz,1H),2.52-2.49(m,1H),2.07-1.96(m,1H),1.36(s,9H)。
Step 2: synthesis of Compound S25
Figure BDA0002412646800000312
Compound S24(190mg,0.46mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S25, which was directly used in the next step without further purification.
And step 3: synthesis of Compound S27
Figure BDA0002412646800000313
Compound S25(150mg,0.48mmol) and compound S26(114mg,0.52mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (360mg,0.95mmol) and DIPEA (340uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S27 as a yellow solid (139mg, 57% yield).1H NMR(400MHz,DMSO)δ11.11(s,1H),8.03(s,1H),7.59(t,J＝7.7Hz,1H),7.18(d,J＝8.5Hz,1H),7.03(d,J＝6.9Hz,1H),6.84-6.69(m,2H),5.06(dd,J＝12.6,4.8Hz,1H),3.37(d,J＝6.0Hz,2H),3.23(d,J＝5.3Hz,2H),2.97-2.79(m,3H),2.65-2.52(m,2H),2.04(t,J＝6.8Hz,3H),1.51-1.42(m,2H),1.36(s,11H)。
And 4, step 4: synthesis of Compound S28
Figure BDA0002412646800000321
Compound S27(140mg,0.27mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S28, which was directly used in the next step without further purification.
And 5: synthesis of Compound 8
Figure BDA0002412646800000322
Compound S15(50mg,0.09mmol) and compound S28(42mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 8 as a yellow solid (61mg, 71% yield).1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.17(s,1H),8.83(s,1H),8.04(t, J ═ 5.1Hz,2H),7.75(d, J ═ 7.8Hz,2H),7.66-7.52(m,4H),7.17(d, J ═ 8.6Hz,1H),7.02(d, J ═ 7.0Hz,1H),6.93(d, J ═ 8.6Hz,2H),6.74(t, J ═ 6.0Hz,1H),5.73-5.61(m,1H),5.33(s,1H),5.06(dd, J ═ 12.9,5.3, 1H),5.00(d, J ═ 10.2, 1H), 4.33 (s,1H),5.06(dd, 3, 1H),5.00(d, J ═ 10.9, 3.3, 1H),5.00(d, 3, 3.3, 3, 2H),3.3, 3H), 5.3, 3.3H, 3H, 3.3.3, 3, 3.3, 3H, 3H, 3H, etc., 5H) 2.14-1.96(m,3H),1.56-1.43(m,8H),1.43-1.35(m, 2H). HRMS (ESI) m/z calculated value C48H55N13O8[M+H]+: 942.4375, found: 942.4369.
example 5: synthetic route to compound 9
Step 1: synthesis of Compound S31
Figure BDA0002412646800000323
Compounds S29(100mg,0.37mmol) and S30(68mg,0.31mmol) were added to a 3mL DMF solution, and after the system was completely dissolved, potassium carbonate (84mg,0.61mmol) was added and the reaction was allowed to warm to 60 ℃ for 6 hours. After the reaction was completed, 30mL of water was added, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S31 as a yellow solid (92mg, 72% yield).1H NMR(400MHz,DMSO)δ11.11(s,1H),7.81(t,J＝7.5Hz,1H),7.54(d,J＝8.3Hz,1H),7.46(d,J＝6.9Hz,1H),6.98(s,1H),5.09(dd,J＝12.0,4.4Hz,1H),4.23(s,2H),3.34(s,2H),2.89(t,J＝13.3Hz,1H),2.68-2.53(m,2H),2.13-1.95(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S32
Figure BDA0002412646800000331
Compound S31(224mg,0.54mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S32, which was directly used in the next step without further purification.
And step 3: synthesis of Compound S33
Figure BDA0002412646800000332
Compound S32(150mg,0.47mmol) and compound S26(114mg,0.52mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (360mg,0.95mmol) and DIPEA (340uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S33(132mg, 55% yield) as a yellow solid.1H NMR(400MHz,CDCl3)δ9.06(s,1H),7.71(t,J＝7.8Hz,1H),7.52(d,J＝7.3Hz,1H),7.27(s,2H),6.76(s,1H),4.98(d,J＝5.9Hz,1H),4.39-4.13(m,2H),3.81-3.63(m,2H),3.23-3.03(m,3H),2.93-2.80(m,2H),2.24(t,J＝7.6Hz,2H),2.19-2.11(m,1H),1.70-1.56(m,2H),1.43(s,11H)。
And 4, step 4: synthesis of Compound S34
Figure BDA0002412646800000333
Compound S33(85mg,0.16mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S34, which was directly used in the next step without further purification.
And 5: synthesis of Compound 9
Figure BDA0002412646800000334
Compound S15(50mg,0.09mmol) and compound S34(42mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography to give compound 9 as a yellow solid (45mg, 53% yield).1H NMR (400MHz, DMSO) δ 11.11(s,1H),10.16(s,1H),8.83(s,1H),8.05(t, J ═ 5.2Hz,2H),7.90-7.70(m,3H),7.68-7.51(m,4H),7.46(d, J ═ 7.2Hz,1H),6.93(d, J ═ 8.7Hz,2H),5.67(dq, J ═ 10.4,6.0Hz,1H),5.33(s,1H),5.09(dd, J ═ 12.8,5.3Hz,1H),5.00(d, J ═ 10.1Hz,1H),4.83(d, J ═ 17.1Hz,1H),4.69(d, J ═ 1H, 5.24, 24H), t, 2.5.5.5.5 (d, J ═ 10.5.1 Hz, 5H), 5.83 (d, J ═ 2H, 5.06 Hz, 5.06H, 5.5.5.5, 5.5.5.5.5, 5, 5.5.5 (d, 3H, 2H, 5, 5.06, 2H, 5.06H, 5, 2H, 5, 3H, 5H, 5, 2H, 5, 2H, 3H, 2H, 5, 2H, 5, 3H, 5, 2H, 5, 2H, 3H, 2H, 5, 2H, 5, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, 2H, etc., 1H) 1.57-1.34(m, 10H). HRMS (ESI) m/z calculated value C48H54N12O9[M+Na]+: 965.4034, found: 965.4001.
example 6: synthetic route to Compound 10
Step 1: synthesis of Compound S36
Figure BDA0002412646800000341
Compounds S16(200mg,0.73mmol) and S35(180mg,0.76mmol) were added to a 5mL solution of DMF and DIPEA (390uL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction was completed, 50mL of water was added to the system, extraction was performed with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentratedAnd (5) condensing to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S36 as a yellow solid (235mg, 66% yield).1H NMR(400MHz,DMSO)δ11.11(s,1H),7.50(t,J＝6.9Hz,1H),7.40-7.27(m,3H),7.20(s,3H),7.01(d,J＝6.6Hz,1H),6.94(d,J＝8.2Hz,1H),5.07(dd,J＝11.5,3.6Hz,1H),4.53(d,J＝3.4Hz,2H),4.08(s,2H),2.89(t,J＝13.4Hz,1H),2.66-2.54(m,2H),2.11-1.98(m,1H),1.38(s,9H)。
Step 2: synthesis of Compound S37
Figure BDA0002412646800000342
Compound S36(160mg,0.33mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S37, which was directly used in the next step without further purification.
And step 3: synthesis of Compound S38
Figure BDA0002412646800000343
Compound S37(250mg,0.64mmol) and compound S26(153mg,0.70mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (485mg,1.28mmol) and DIPEA (500uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S38(207mg, 54% yield) as a yellow solid.1H NMR(400MHz,DMSO)δ11.12(s,1H),8.25(s,1H),7.50(t,J＝7.6Hz,1H),7.31(d,J＝7.6Hz,2H),7.19(d,J＝7.7Hz,3H),7.01(d,J＝7.0Hz,1H),6.93(d,J＝8.4Hz,1H),6.79(s,1H),5.07(dd,J＝12.8,4.9Hz,1H),4.53(d,J＝5.3Hz,2H),4.22(d,J＝5.1Hz,2H),2.89(d,J＝4.9Hz,3H),2.67-2.53(m,2H),2.10(t,J＝7.1Hz,2H),2.06-1.97(m,1H),1.47(d,J＝6.9Hz,2H),1.36(s,11H)。
And 4, step 4: synthesis of Compound S39
Figure BDA0002412646800000351
Compound S38(100mg,0.17mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S39, which was directly used in the next step without further purification.
And 5: synthesis of Compound 10
Figure BDA0002412646800000352
Compound S15(50mg,0.09mmol) and compound S39(50mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 10(49mg, 54% yield) as a yellow solid.1H NMR (400MHz, DMSO) δ 11.12(s,1H),10.18(s,1H),8.83(s,1H),8.28(t, J ═ 5.8Hz,1H),8.05(t, J ═ 7.4Hz,1H),7.77(t, J ═ 12.3Hz,2H),7.59(t, J ═ 14.1Hz,3H),7.50-7.45(m,1H),7.30(d, J ═ 8.1Hz,2H),7.23-7.18(m,3H),7.01(t, J ═ 5.3Hz,1H),6.92(t, J ═ 9.3Hz,3H),5.67(dq, J ═ 11.1,5.9, 1H),5.34(s, 1.5, 5H), 6.92(t, J ═ 9.3Hz,3H),5.67 (ddq, 11.1,5.9, 1H), 3H, 5, 4H, 4, 3H, 5, 4H, 3H, 4H, 3H, 4H, 3H, 4H, 3H, 4H, 3H, 4H, 3H, 3H, 3H, 3H, 4H, 3H, 4H, 6, 4H, 3H, 4H, 3H, 3H, 3H, 4H, 3H, and so on (d, 6.6.6.6.6.6, 6.6, 6, 6.6.6, 6, 6.6, 6H, 6H, 6, 6H) 2.95-2.83(m,3H),2.70-2.53(m,5H),2.14(t, J ═ 7.2Hz,2H),2.07-2.01(m,1H),1.56-1.38(m, 10H). HRMS (ESI) m/z calculated value C54H59N13O8[M+H]+: 1018.2663, found: 1018.2642.
example 7: synthetic route to compound 11
Step 1: synthesis of Compound S41
Figure BDA0002412646800000353
Compounds S29(100mg,0.37mmol) and S40(82mg,0.37mmol) were added to a 3mL DMF solution, and after the system was completely dissolved, potassium carbonate (100mg,0.74mmol) was added and the reaction was allowed to warm to 60 ℃ for 6 hours. After the reaction was completed, 30mL of water was added, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S41 as a yellow solid (65mg, 43% yield).1H NMR(400MHz,DMSO)δ11.12(s,1H),7.83(t,J＝7.7Hz,1H),7.59(d,J＝8.5Hz,1H),7.55(d,J＝7.5Hz,2H),7.48(d,J＝7.1Hz,1H),7.43(d,J＝7.5Hz,2H),5.39(s,2H),5.11(dd,J＝12.6,4.8Hz,1H),4.47(s,2H),2.97-2.81(m,1H),2.66-2.53(m,2H),2.11-1.97(m,1H)。
Step 2: synthesis of Compound S42
Figure BDA0002412646800000361
Compound S41(60mg,0.14mmol) was added to a mixed solution of 1M HCl (2mL) and ether (2mL), triphenylphosphine (38mg, 0.14mmol) was added under ice bath, and after completion of addition, the mixture was warmed to room temperature to react for 12 hours. After the reaction, 4M sodium carbonate solution was added to adjust PH to 10, 5mL water was added, ethyl acetate was extracted, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S42(34mg, 61% yield) as a yellow solid.
And step 3: synthesis of Compound S43
Figure BDA0002412646800000362
Compound S42(350mg,0.92mmol) and compound S26(200mg,0.92mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (700mg,1.85mmol) and DIPEA (500uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S43 as a yellow solid (377mg, 69% yield).
And 4, step 4: synthesis of Compound S44
Figure BDA0002412646800000363
Compound S43(350mg,0.59mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S44, which was directly used in the next step without further purification.
And 5: synthesis of Compound 11
Figure BDA0002412646800000364
Compound S15(50mg,0.09mmol) and compound S44(50mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 11 as a yellow solid (62mg, 68% yield).1H NMR (400MHz, DMSO) δ 11.08(s,1H),10.17(s,1H),8.83(s,1H),8.33(s,1H),8.05(s,1H),7.84-7.72(m,3H),7.69-7.52(m,4H),7.44(d, J-7.2 Hz,3H),7.28(d, J-7.3 Hz,2H),6.92(d, J-7.5 Hz,2H),5.66(dt, J-15.9, 8.0Hz,1H),5.42-5.23(m, dd3H), 5.09(d, J-12.3, 4.6Hz,1H),5.00(d, J-10.0, 1H),4.83(d, 17.17H), 4.63 (d, 2H), 4.27H, 2H, 3, 2H), 3.9-2H, 3H, 2H, 3H, 2H, 3H, 5.00(d, 2H, 3H, 2H, 3H, 2H, 3H, 2H, 3H, etc., 1H) 1.57-1.39(m, 10H). HRMS (ESI) m/z calculated value C54H58N12O9[M+H]+: 1019.4528, found: 1019.4504.
example 8: synthetic route to compound 12
Step 1: synthesis of Compound S46
Figure BDA0002412646800000371
Compounds S16(500mg,1.81mmol) and S45(450mg,1.81mmol) were added to a 10mL DMF solution, DIPEA (900uL) was added under nitrogen, the reaction was warmed to 90 ℃ and reacted for 12 hours. After the reaction is finished, 150mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S46(572mg, 63% yield) as a yellow solid.1H NMR(400MHz,DMSO)δ11.09(s,1H),7.59(t,J＝7.8Hz,1H),7.15(d,J＝8.6Hz,1H),7.04(d,J＝7.0Hz,1H),6.72(s,1H),6.61(t,J＝5.5Hz,1H),5.06(dd,J＝12.9,5.3Hz,1H),3.62(t,J＝5.3Hz,2H),3.58-3.54(m,2H),3.53-3.50(m,2H),3.47(d,J＝5.4Hz,2H),3.38(t,J＝6.0Hz,2H),3.06(dd,J＝11.5,5.6Hz,2H),2.94-2.81(m,1H),2.66-2.53(m,2H),2.08-1.97(m,1H),1.36(s,9H)。
Step 2: synthesis of Compound S47
Figure BDA0002412646800000372
Compound S46(520mg,1.03mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane, and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S47, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 12
Figure BDA0002412646800000373
Compound S15(50mg,0.09mmol) and compound S47(42mg,0.10mmol) were added to 3mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is completed, the reaction solution is fed into the systemAdding 30mL of water, extracting with ethyl acetate, combining organic phases, washing with saturated saline solution, drying with anhydrous sodium sulfate, filtering, collecting filtrate and concentrating to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 12 as a yellow solid (44mg, 53% yield).1H NMR (400MHz, DMSO) δ 11.02(s,1H),10.08(s,1H),8.74(s,1H),7.96(t, J ═ 7.2Hz,1H),7.75-7.60(m,2H),7.59-7.35(m,4H),6.99(d, J ═ 8.6Hz,1H),6.92(d, J ═ 7.0Hz,1H),6.82(d, J ═ 8.6Hz,2H),6.51(t, J ═ 5.5Hz,1H),5.64-5.51(m,1H),5.25(s,1H),4.96(dd, J ═ 13.0,5.4Hz,1H),4.91(d, J ═ 10.2, 1H),4.73(d, 1H),4.96(dd, 3.7H), 3.7H), 3.7 (d, 3.7H), 3.7 (d, 3.6, 3.7H, 3, 3.7 (d, 3.7H), 1H) 2.56-2.44(m,5H),2.00-1.86(m,1H),1.37(s, 6H). HRMS (ESI) m/z calculated value C47H54N12O9[M+H]+: 931.4215, found: 931.4231.
example 9: synthetic route to compound 13
Step 1: synthesis of Compound S49
Figure BDA0002412646800000381
Compounds S16(236mg,0.86mmol) and S48(250mg,0.86mmol) were added to a 5mL solution of DMF and DIPEA (600uL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S49 as a yellow solid (248mg, 46% yield).1H NMR(400MHz,DMSO)δ11.10(s,1H),7.58(t,J＝7.8Hz,1H),7.15(d,J＝8.6Hz,1H),7.04(d,J＝7.0Hz,1H),6.74(s,1H),6.61(t,J＝5.3Hz,1H),5.06(dd,J＝12.8,5.2Hz,1H),3.62(t,J＝5.1Hz,2H),3.59-3.42(m,10H),3.36(d,J＝6.0Hz,2H),3.05(dd,J＝11.3,5.5Hz,2H),2.96-2.80(m,1H),2.65-2.52(m,2H),2.08-1.96(m,1H),1.36(s,9H)。
Step 2: synthesis of Compound S50
Figure BDA0002412646800000382
Compound S49(220mg,0.40mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S50, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 13
Figure BDA0002412646800000391
Compound S15(120mg,0.22mmol) and compound S50(100mg,0.22mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (170mg,0.45mmol) and DIPEA (100uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 13 as a yellow solid (115mg, 53% yield).1H NMR (400MHz, DMSO) δ 11.11(s,1H),10.16(s,1H),8.83(s,1H),8.07(t, J ═ 16.1Hz,1H),7.75(d, J ═ 5.4Hz,2H),7.64-7.51(m,4H),7.09(d, J ═ 8.6Hz,1H),7.02(d, J ═ 6.9Hz,1H),6.93(d, J ═ 8.2Hz,2H),6.61-6.51(m,1H),5.67(dq, J ═ 10.5,5.7Hz,1H),5.34(s,1H),5.10-4.96(m,2H),4.83(d, J ═ 17.2Hz,1H),4.67 (J ═ 4.67, 3.7H), 3.7H), 3.3.7H, 3.7H, 3H, 3.7H, 3H, 2.07-2.01(m,1H),1.47(s, 6H). HRMS (ESI) m/z calculated value C49H58N12O10[M+H]+: 975.4477, found: 975.4524.
example 10: synthetic route to compound 14
Step 1: synthesis of Compound S52
Figure BDA0002412646800000392
Compounds S16(500mg,1.81mmol) and S51(600mg,1.81mmol) were added to a 10mL DMF solution, DIPEA (600uL) was added under nitrogen, the reaction was warmed to 90 ℃ and reacted for 12 hours. After the reaction is finished, 150mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S52 as a yellow solid (728mg, 68% yield).1H NMR(400MHz,DMSO)δ11.10(s,1H),7.58(t,J＝7.6Hz,1H),7.15(d,J＝8.5Hz,1H),7.04(d,J＝6.9Hz,1H),6.74(s,1H),6.61(s,1H),5.06(dd,J＝12.5,4.1Hz,1H),3.71-3.61(m,2H),3.59-3.44(m,14H),3.36(s,2H),3.05(d,J＝5.1Hz,2H),2.89(t,J＝13.4Hz,1H),2.65-2.52(m,2H),2.09-1.94(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S53
Figure BDA0002412646800000401
Compound S52(200mg,0.34mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S53, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 14
Figure BDA0002412646800000402
Compound S15(55mg,0.10mmol) and compound S53(50mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (76mg,0.20mmol) and DIPEA (100uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 14 as a yellow solid (63mg, 65% yield).1H NMR(400MHz,DMSO)δ11.10(s,1H),10.18(s,1H),8.83(s,1H),8.09-8.01(m,1H),7.75(d, J ═ 7.4Hz,1H),7.68-7.51(m,4H),7.12(d, J ═ 8.4Hz,1H),7.03(d, J ═ 6.9Hz,1H),6.95(d, J ═ 8.0Hz,2H),6.59(s,1H),5.67(td, J ═ 15.7,6.8Hz,1H),5.34(s,1H),5.10-4.95(m,2H),4.83(d, J ═ 17.1Hz,1H),4.75-4.62(m,2H),3.62-3.42(m,18H),3.33-3.09(m,8H),2.94-2.53(m,6H), 2.07-1H (m,1H), 1.07-1H), 1.46 (m, 4H). HRMS (ESI) m/z calculated value C51H62N12O11[M+H]+: 1019.4739, found: 1019.4739.
example 11: synthetic route to compound 15
Step 1: synthesis of Compound S55
Figure BDA0002412646800000403
Compounds S16(240mg,0.86mmol) and S54(350mg,0.86mmol) were added to a 5mL DMF solution, DIPEA (300uL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S55 as a yellow solid (428mg, 79% yield).1H NMR(400MHz,DMSO)δ11.12(s,1H),7.59(t,J＝7.8Hz,1H),7.15(d,J＝8.6Hz,1H),7.04(d,J＝7.0Hz,1H),6.77(s,1H),6.62(t,J＝5.4Hz,1H),5.06(dd,J＝12.9,5.3Hz,1H),3.62(t,J＝5.1Hz,2H),3.57-3.46(m,18H),3.37(d,J＝6.0Hz,2H),3.05(dd,J＝11.5,5.6Hz,2H),2.95-2.81(m,1H),2.66-2.53(m,2H),2.08-1.97(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S56
Figure BDA0002412646800000411
Compound S55(200mg,0.31mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S56, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 15
Figure BDA0002412646800000412
Compound S15(50mg,0.09mmol) and compound S56(54mg,0.10mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (70mg,0.18mmol) and DIPEA (200uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 15(49mg, 51% yield) as a yellow solid.1H NMR (400MHz, DMSO) δ 11.12(s,1H),10.18(s,1H),8.84(s,1H),8.06(s,1H),7.77(d, J ═ 4.8Hz,2H),7.70-7.49(m,4H),7.12(d, J ═ 8.6Hz,1H),7.04(d, J ═ 7.0Hz,1H),6.94(d, J ═ 8.3Hz,2H),6.60(t, J ═ 5.1Hz,1H),5.67(dq, J ═ 10.9,5.9Hz,1H),5.35(s,1H),5.06(dd, J ═ 12.9,5.1, 1H),5.00(d, J ═ 10.1, 1H), 4.81H, 4(s,1H), 3.3H, 2H), 3.3.3H, 3H, 3.3H, 3H, 3.3H, 3H, etc., 1H) 2.69-2.55(m,5H),2.09-2.01(m,1H),1.47(s, 6H). HRMS (ESI) m/z calculated value C53H66N12O12[M+H]+: 1063.5001, found: 1063.4985.
example 12: synthetic route to compound 16
Step 1: synthesis of Compound S58
Figure BDA0002412646800000413
Compounds S16(1g,3.62mmol) and S57(1.54g,3.62mmol) were added to a 10mL DMF solution, DIPEA (1.3mL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 150mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. Coarse product warp-knitted fabricSeparation and purification by gel column chromatography gave compound S58 as a yellow solid (1.82g, 74% yield).1H NMR(400MHz,DMSO)δ11.10(s,1H),7.59(t,J＝7.7Hz,1H),7.15(d,J＝8.5Hz,1H),7.04(d,J＝6.9Hz,1H),6.75(s,1H),6.61(s,1H),5.06(dd,J＝12.5,4.3Hz,1H),3.72-3.62(m,2H),3.58-3.46(m,22H),3.37(s,2H),3.06(d,J＝5.3Hz,2H),2.89(t,J＝13.6Hz,1H),2.66-2.52(m,2H),2.09-1.95(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S59
Figure BDA0002412646800000421
Compound S58(1g,1.47mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S59, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 16
Figure BDA0002412646800000422
Compound S15(45mg,0.08mmol) and compound S59(48mg,0.08mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (63mg,0.17mmol) and DIPEA (100uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 16(53mg, 58% yield) as a yellow solid.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.17(s,1H),8.83(s,1H),8.12-8.00(m,1H),7.76(d, J ═ 5.1Hz,2H),7.63-7.54(m,4H),7.13(d, J ═ 8.6Hz,1H),7.04(d, J ═ 6.8Hz,1H),6.93(d, J ═ 8.0Hz,2H),6.67-6.58(m,1H),5.67(dd, J ═ 16.0,9.2Hz,1H),5.33(s,1H),5.09-4.97(m,2H),4.83(d, J ═ 17.0, 1H), 4.75-4.61H, 3.75 (m, 3.60H), 3.50-4.52H (m, 3.50H), 3.52H, 3.70-4.70H, 3.52 (m, 3.50H, 3.52H, 3.50H, 3.70H, 3.52H, 3.70H, 3H, 1H) 1.47(s, 6H). HRMS (ESI) m/z calculated value C55H70N12O13[M+Na]+: 1129.5083, found: 1129.5112.
example 13: synthetic route to compound 17
Step 1: synthesis of Compound S61
Figure BDA0002412646800000431
Compounds S16(700mg,2.56mmol) and S60(1.2g,2.56mmol) were added to a 10mL DMF solution, DIPEA (800uL) was added under nitrogen, and the reaction was warmed to 90 ℃ for 12 hours. After the reaction is finished, 150mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S61 as a yellow solid (1.44g, 78% yield).1H NMR(400MHz,DMSO)δ11.11(s,1H),7.59(t,J＝7.8Hz,1H),7.15(d,J＝8.6Hz,1H),7.04(d,J＝7.0Hz,1H),6.76(t,J＝5.2Hz,1H),6.61(t,J＝5.6Hz,1H),5.06(dd,J＝12.9,5.3Hz,1H),3.62(t,J＝5.2Hz,2H),3.57-3.46(m,26H),3.39-3.35(m,2H),3.05(dd,J＝11.8,5.9Hz,2H),2.95-2.82(m,1H),2.64-2.53(m,2H),2.08-1.97(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S62
Figure BDA0002412646800000432
Compound S61(350mg,0.49mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S62, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 17
Figure BDA0002412646800000433
Compound S15(87mg,0.16mmol) and compoundS62(100mg,0.16mmol) was added to 5mL of DMF, and after dissolving with stirring, HATU (125mg,0.32mmol) and DIPEA (100uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 17(94mg, 51% yield) as a yellow solid.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.18(s,1H),8.84(s,1H),8.30-8.18(m,1H),8.06(t, J ═ 11.6Hz,1H),7.76(d, J ═ 7.1Hz,1H),7.68-7.51(m,4H),7.14(d, J ═ 7.8Hz,1H),7.04(d, J ═ 6.4Hz,1H),6.95(d, J ═ 7.5Hz,2H),6.60(s,1H),5.67(dd, J ═ 16.2,8.7Hz,1H),5.33(s,1H),5.06(d, J ═ 10.9, 1H),5.00(d, J ═ 10.9, 1H), 10.00 (d, J ═ 10.8.7H), 3.69 (d, 3.18H), 3.18(d, 3.3.3H), 3.3.3.3H, 3.3.3 (m,3, 3.3, 3, 1H) 1.47(s, 6H). HRMS (ESI) m/z calculated value C57H74N12O14[M+H]+: 1151.5526, found: 1151.5562.
example 14: synthetic route to compound 18
Step 1: synthesis of Compound S64
Figure BDA0002412646800000441
Compounds S16(360mg,1.29mmol) and S63(660mg,1.29mmol) were added to a 5mL DMF solution, DIPEA (500uL) was added under nitrogen, the reaction was warmed to 90 ℃ and reacted for 12 hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S64 as a yellow solid (674mg, 68% yield).1H NMR(400MHz,DMSO)δ11.09(s,1H),7.59(t,J＝7.6Hz,1H),7.15(d,J＝8.5Hz,1H),7.04(d,J＝6.8Hz,1H),6.73(s,1H),6.61(s,1H),5.06(dd,J＝12.5,3.9Hz,1H),3.67-3.60(m,2H),3.57-3.44(m,30H),3.37(s,2H),3.06(d,J＝5.0Hz,2H),2.89(t,J＝13.4Hz,1H),2.67-2.52(m,2H),2.09-1.96(m,1H),1.37(s,9H)。
Step 2: synthesis of Compound S65
Figure BDA0002412646800000442
Compound S64(250mg,0.33mmol) was added to a mixed solvent of 2mL TFA and 4mL dichloromethane and reacted at room temperature for two hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure to obtain compound S65, which was directly used in the next step without further purification.
And step 3: synthesis of Compound 18
Figure BDA0002412646800000443
Compound S15(80mg,0.15mmol) and compound S65(98mg,0.15mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (112mg,0.30mmol) and DIPEA (80uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 18(112mg, 64% yield) as a yellow solid.1H NMR (400MHz, DMSO) δ 11.10(s,1H),10.16(s,1H),8.83(s,1H),8.07(d, J ═ 19.8Hz,1H),7.84-7.73(m,2H),7.66-7.53(m,4H),7.14(d, J ═ 8.5Hz,1H),7.04(d, J ═ 6.9Hz,1H),6.94(d, J ═ 8.1Hz,2H),6.68-6.54(m,1H),5.67(ddd, J ═ 14.3,8.7,4.2Hz,1H),5.33(s,1H),5.11-4.96(m,2H),4.83(d, J ═ 17.1, 1H), 4.63-4.73 (m, 3.3H), 3.85 (m,3H), 3.3H, 3H), 3.6.6.6.06 (m,3H), 3H), 3.6.7 (d, 3H), 3H), 2.72-2.53(m,6H),2.06-1.98(m,1H),1.47(s, 6H). HRMS (ESI) m/z calculated value C59H78N12O15[M+H]+: 1195.5788, found: 1195.5774.
example 15: synthetic route to compound 19
Step 1: synthesis of Compound S68
Figure BDA0002412646800000451
Compound S66(166mg,0.45mmol), compound S67(38mg,0.45mmol), PdCl under nitrogen2(PPh3)2(16mg,0.02mmol) and cuprous iodide (4mg,0.02mmol) were sequentially added to 10mL of DME, stirred to dissolve, triethylamine (182mg,1.8mmol) was added, and the reaction was refluxed for 12 hours. After the reaction is finished, 10mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S68 as a white solid (60mg, 41% yield). LC-Mass (ESI) m/z C18H18N2O4[M+H]+：327.24。
Step 2: synthesis of Compound S69
Figure BDA0002412646800000452
Compound S68(50mg,0.15mmol) was added to 10mL of dichloromethane under nitrogen, and phosphorus tribromide (182mg,1.8mmol) was added under ice-bath for reaction for 15 minutes. After the reaction is finished, 10mL of water is added into the system, dichloromethane is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, filtrate is collected and concentrated to obtain a product S69, and the product S69 is quickly put into the next step without purification.
And step 3: synthesis of Compound 19
Figure BDA0002412646800000453
Compound S69(58mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF under nitrogen, potassium carbonate (62mg,0.45mmol) was added at room temperature, the mixture was warmed to 60 ℃ and reacted for 6 hours. After completion of the reaction, 50mL of water was added to the system, extraction was performed with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to give compound 19 as a white solid (62mg, 53% yield))。1H NMR(400MHz,DMSO)δ11.04(s,1H),10.19(s,1H),8.68–8.05(m,2H),7.74(d,J＝7.3Hz,2H),7.62–7.48(m,2H),7.01(d,J＝7.9Hz,2H),5.75–5.54(m,1H),5.32(s,1H),5.22(d,J＝13.1Hz,1H),5.03(d,J＝11.2Hz,1H),4.81(t,J＝19.5Hz,1H),4.70(s,2H),4.38(dd,J＝57.2,16.8Hz,2H),3.95–3.66(m,6H),3.45–3.34(m,2H),3.18–3.03(m,4H),2.93(d,J＝13.2Hz,1H),2.70(d,J＝32.4Hz,4H),2.61(d,J＝16.2Hz,1H),2.49–2.37(m,1H),2.04(s,1H),1.47(s,6H)。
Example 16: synthetic route to compound 20
Step 1: synthesis of Compound S70
Figure BDA0002412646800000461
Compound S68(50mg,0.15mmol) and 10% palladium on carbon catalyst (5mg) were added to 10mL of methanol under nitrogen atmosphere, and the hydrogen gas was replaced, followed by reaction for 2 hours. After the reaction was completed, the palladium on carbon was removed by filtration, and the filtrate was collected and concentrated to give S70(48mg, 98% yield) as a solid. LC-Mass (ESI) m/z C18H24N2O4[M+H]+：331.46。
Step 2: synthesis of Compound S71
Figure BDA0002412646800000462
Compound S70(50mg,0.15mmol) was added to 10mL of dichloromethane under nitrogen, and phosphorus tribromide (182mg,1.8mmol) was added under ice-bath for reaction for 15 minutes. After the reaction is finished, 10mL of water is added into the system, dichloromethane is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, filtrate is collected and concentrated to obtain a product 71, and the product is quickly put into the next step without purification.
And step 3: synthesis of Compound 20
Figure BDA0002412646800000463
Compound S71(58mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF under nitrogen, potassium carbonate (62mg,0.45mmol) was added at room temperature, the mixture was warmed to 60 ℃ and reacted for 6 hours. After completion of the reaction, 50mL of water was added to the system, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to give compound 20 as a white solid (56mg, 47.7% yield). 1H NMR (400MHz, DMSO) δ 11.05(s,1H),10.18(s,1H), 8.68-8.13 (m,3H),7.92(d, J ═ 7.3Hz,1H), 7.52-7.36 (m,2H),6.95(d, J ═ 7.2Hz,2H), 5.73-5.54 (m,1H),5.32(s,1H),5.20(d, J ═ 12.8Hz,1H),5.02(d, J ═ 11.2Hz,1H),4.81(d, J ═ 12.5Hz,1H),4.70(s,2H),4.38(dd, J ═ 56.8,16.7Hz,2H), 3.91-3.60 (m,8H), 3.51-3.41 (m,
4H),3.16–2.99(m,4H),2.92(d,J＝13.4Hz,1H),2.71(d,J＝32.4Hz,4H),2.61(d,J＝16.6Hz,1H),2.48–2.35(m,1H),2.04(s,1H),1.46(s,6H)。
example 17: synthetic route to compound 21
Step 1: synthesis of Compound S73
Figure BDA0002412646800000471
Compound S66(166mg,0.45mmol), compound S72(44mg,0.45mmol), PdCl under nitrogen2(PPh3)2(16mg,0.02mmol) and cuprous iodide (4mg,0.02mmol) were sequentially added to 10mL of DME, stirred to dissolve, triethylamine (182mg,1.8mmol) was added, and the reaction was refluxed for 12 hours. After the reaction is finished, 10mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S73 as a white solid (68mg, 45% yield). LC-Mass (ESI) m/z C18H16N2O5[M+H]+：341.64。
Step 2: synthesis of Compound 21
Figure BDA0002412646800000472
Compound S73(51mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (112mg,0.30mmol) and DIPEA (80uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 21 as a yellow solid (82mg, 69% yield).
1H NMR(400MHz,DMSO)δ11.04(s,1H),10.19(s,1H),8.84(s,1H),8.05(s,1H),7.74(dd,J＝19.8,7.3Hz,2H),7.61(s,3H),7.52(t,J＝7.4Hz,1H),6.95(d,J＝7.9Hz,2H),5.78–5.58(m,1H),5.34(s,1H),5.17(d,J＝12.7Hz,1H),5.00(d,J＝10.0Hz,1H),4.81(t,J＝19.5Hz,1H),4.70(s,2H),4.39(dd,J＝58.5,17.8Hz,2H),3.64(s,4H),3.45–3.31(m,2H),3.18–2.99(m,4H),2.93(t,J＝13.4Hz,1H),2.70(d,J＝36.9Hz,4H),2.60(d,J＝16.6Hz,1H),2.48–2.37(m,1H),2.04(s,1H),1.47(s,6H)。
Example 18: synthetic route to compound 22
Step 1: synthesis of Compound S74
Figure BDA0002412646800000481
Compound S73(70mg,0.20mmol) and 10% palladium on carbon catalyst (7mg) were added to 10mL of methanol under nitrogen atmosphere, and the hydrogen gas was replaced, followed by reaction for 2 hours. After the reaction was completed, the palladium on carbon was removed by filtration, and the filtrate was collected and concentrated to give S74(66mg, 95% yield) as a solid. LC-Mass (ESI) m/z C18H20N2O5[M+H]+：344.93。
Step 2: synthesis of Compound 22
Figure BDA0002412646800000482
Compound S74(51mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (112mg,0.30mmol) and DIPEA (80uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound 22 as a yellow solid (68mg, 57% yield). 1H NMR (400MHz, DMSO) δ 11.04(s,1H),10.18(s,1H),8.83(s,1H),8.02(s,1H),7.83(d, J ═ 7.6Hz,2H),7.61(s,3H),7.52(t, J ═ 7.5Hz,1H), 7.01-6.58 (m,2H), 5.80-5.59 (m,1H),5.34(s,1H),5.17(d, J ═ 12.7Hz,1H),5.00(d, J ═ 10.0Hz,1H),4.81(t, J ═ 19.7Hz,1H),4.70(s,2H),4.39 (J ═ 58.5,17.8, 2H),3.64(s, 3.64, 3.51H), 3.7 Hz,1H, 4.70(s,2H),4.39(d, J ═ 58.5,17.8, 2H),3.64 (d, 3.51, 3.7H), 3.7H, 1H), 4.51, 3.50H, 3.31H, 3.51 (d, 3.50H), 3.6H, 1H), 4.50H, 1H, and so as to 3H.
Example 19: synthetic route to compound 23
Step 1: synthesis of Compound S77
Figure BDA0002412646800000491
Compound S75(64mg,0.15mmol) and compound S76(25mg,0.15mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (112mg,0.30mmol) and DIPEA (80uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S77(42mg, 49% yield) as a yellow solid. LC-Mass (ESI) m/z C26H35BrN4O4S[M+H]+：579.17。
Step 2: synthesis of Compound 23
Figure BDA0002412646800000492
Under the protection of nitrogen, the compoundS77(87mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF, potassium carbonate (62mg,0.45mmol) was added at room temperature, the temperature was raised to 60 ℃ and the reaction was allowed to proceed for 6 hours. After completion of the reaction, 50mL of water was added to the system, extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected and concentrated to give compound 23(61mg, 42.3% yield) as a white solid. HRMS (ESI) m/z calculated value C52H64N12O6S[M+H]+: 985.5191, found: 985.5174.
example 20: synthetic route to compound 24
Step 1: synthesis of Compound S79
Figure BDA0002412646800000493
Compound S75(64mg,0.15mmol) and compound S78(29mg,0.15mmol) were added to 5mL of DMF, and after dissolving with stirring, HATU (112mg,0.30mmol) and DIPEA (80uL) were added and reacted at room temperature for two hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, and filtrate is collected and concentrated to obtain a crude product. The crude product was isolated and purified by silica gel column chromatography to give compound S79 as a yellow solid (41mg, 47% yield). LC-Mass (ESI) m/z C28H39BrN4O4S[M+H]+：607.01。
Step 2: synthesis of Compound 24
Figure BDA0002412646800000501
Compound S79(91mg,0.15mmol) and compound S13(73mg,0.15mmol) were added to 5mL of DMF under nitrogen, potassium carbonate (62mg,0.45mmol) was added at room temperature, the mixture was warmed to 60 ℃ and reacted for 6 hours. After the reaction is finished, 50mL of water is added into the system, ethyl acetate is used for extraction, organic phases are combined, the mixture is washed by saturated saline solution, dried by anhydrous sodium sulfate and filtered, filtrate is collected and concentrated to obtain white solid compoundSubstance 24(63mg, 41% yield). HRMS (ESI) m/z calculated value C54H68N12O6S[M+H]+: 1013.5184, found: 1013.5160.
test example 1: kinase binding assays.
Screening model WEE1 kinase protein;
the screening method comprises the following steps of preparing a Protocol name WEE 1;
instrument, Envision (Perkinelmer, USA);
materials WEE1 protein was purchased from eurofins; kinase Tracer178 from Thermo Fisher Scientific; Anti-GST was purchased from Cisbio;
the binding reaction is carried out for 1h by adding Eu labeled GST antibody, WEE1 and Tracer 178. The binding of Tracer178 and the antibody to the kinase results in a high degree of FRET, whereas the use of a kinase inhibitor instead of a Tracer results in a loss of FRET.
WEE1 Activity assay Using a LanthaScreenTMKinase binding assays. The GST label carried by the N end of WEE1 protein molecule interacts with Eu-labeled anti-GST antibody, and Eu luminescent group can be specifically combined with Tracer178 carrying fluorescent group, when Eu and Tracer178 are close to each other, fluorescence resonance energy transfer can occur, and fluorescence signal is generated. In EnvisinTMThe fluorescence values are read at the emission wavelengths of 620nm and 665nm by using 320nm laser excitation, and the change of the read fluorescence values reflects the binding capacity of WEE1 protein and the probe. The specific experimental procedures and considerations are as follows: 1, diluting a compound to be detected according to a certain proportion, and adding the diluted compound to a 384-well plate; 2 enzyme buffer, antibody and Tracer178 were added to the respective assay wells, while DMSO solvent control empty and AZD1775 positive compound control empty were set. The total reaction volume was 10. mu.L, and the reaction system contained: containing the band assay compounds dissolved in DMSO at a final concentration of 2%, 0.4 ng/. mu.L WEE1, 1nM Eu-Anti-GST, 70nM Tracer178, 10mM MgCl2,1mM DTT,1 Xkinase buffer, in 3 replicates per experimental well; 3, incubating at room temperature for 1h, detecting fluorescence values of 620nm and 665nm by using Envisin TM, and calculating a ratio of 665nm to 620 nm; 4 data were analyzed using GraphPad, curves were fitted, and IC50 was calculated.
As shown in table 3 below, with WEE1 inhibitorAZD1775 as a positive control, IC of Compounds 1-24 on WEE1 protein50All values are greater than AZD1775 (IC)5017.28 ± 2.58nM), indicating that compound 1-24 binds less strongly to WEE1 protein than the positive control AZD 1775.
TABLE 3
Figure BDA0002412646800000502
Figure BDA0002412646800000511
Test example 2: and (4) performing a cell toxicity test.
Screening models:MV-4-11；SUM149PT；A498；
the screening method comprises the following steps:protocol name suspension cells (3 days);
instrument SpectraMAX 340;
96plate (spring) material; cells; medium; DMSO; MTS;
the process is that the cell survival rate is detected by using an MTS method: 1. sucking the culture medium of the cells growing in the logarithmic phase, slightly blowing and beating, and counting; 2. seeding 90ul in 96-well plates at the corresponding cell density; 3. adding 10ul of compound, each compound having a concentration gradient, each concentration having three or more wells, each concentration being added to a corresponding well; the final concentration of DMSO was 0.2%; 4.5% CO2Culturing at 37 deg.C for 3days, and adding 20ul MTS; after 3 hours incubation at 5.37 ℃ 490nm (L1) light absorption was measured using SpectraMAX 340, reference wavelength 690nm (L2), values (L1-L2) were plotted against different inhibitor concentrations, percent activity (%) -Compound OD-BLANK OD/DMSO OD-BLANK OD 100%, IC was fit using GraphPad to the formula50。
Data processing and results description:
the activity of the sample is tested under a single concentration condition, e.g., 20. mu.g/ml, for primary screening. For samples that exhibit activity under certain conditions, e.g., an Inhibition% Inhibition of greater than 50, the testActive dose dependence, i.e. IC50/EC50Values, obtained by nonlinear fitting of sample concentrations through sample activity, were calculated as Graphpad Prism 4, the model used for fitting was sigmoidal dose-response (variable slope), and for most inhibitor screening models, the bottom and top of the fitted curve were set at 0 and 100. In general, each sample was tested with multiple wells (n.gtoreq.2) and the results were expressed as Standard Deviation (SD) or Standard Error (SE).
As shown in table 4 below, compounds 1-24 acted on three tumor cell lines with the WEE1 inhibitor AZD1775 as a positive control, including: MV-4-11 (leukemia cell line), SUM149PT (breast cancer cell line) and A498 (renal cancer cell line). Among them, compound 2, in particular, showed extremely superior anti-tumor proliferation activity in vitro compared to other compounds in table 4, including the positive control AZD 1775: MV-4-11(IC50 ═ 46.00 ± 6.87nM), SUM149PT (IC50 ═ 217.67 ± 38.57nM), and a498 (IC)50＝163.86±16.20nM)。
TABLE 4
Figure BDA0002412646800000512
Figure BDA0002412646800000521
Test example 3: western blotting (Western blotting) experiment
The method comprises the following steps: 1) inoculating cells in a 6-well plate according to an experimental scheme, inoculating 100 ten thousand cells in each well, stabilizing for several hours, and then treating the cells in each well with corresponding compounds; 2) after compound treatment was complete, cells were harvested by centrifugation, washed twice with PBS and aspirated off; 3) and (3) denaturing and cracking: mu.l of 1 × loading (62.5mM Tris-HCI, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, 1% DTT) was added to each well and the cells were blown up, avoiding blowing up air bubbles as much as possible, and stored in a 100 ℃ metal water bath for 15min at-20 ℃. 4) SDS-PAGE electrophoresis: preparing protein electrophoresis gel according to a Tricine gel formula, adding an inner tank electrophoresis buffer solution and an outer tank electrophoresis buffer solution, loading 10 mu l of each lane, after loading is finished, carrying out constant current electrophoresis, and carrying out 20mA treatment on each gel; 5) protein membrane conversion: after electrophoresis is finished, transferring the protein to a nitrocellulose membrane by using a BioRad wet-conversion electrophoresis instrument system, and calculating membrane conversion time frequently according to 1min of every 1KD protein under the condition of constant voltage of 100 volts; 6) sealing the strip: after the membrane transfer is finished, cutting off the target strip, placing the target strip in 5% skimmed milk sealing solution prepared by TBST in advance, sealing the target strip for 1 hour on a rocking bed at room temperature, and sealing phosphorylated proteins for 1 hour by using 5% BSA sealing solution at room temperature; 7) primary antibody incubation: after the blocking is finished, abandoning the supernatant blocking solution, simply washing the strip with TBST, removing the floating color, diluting the primary antibody to be detected with TBST according to the antibody using instruction, and incubating overnight at 4 ℃; after incubation, the strips were washed 3 times with 5mL TBST per strip, 5min each time; 8) and (3) secondary antibody incubation: anti-rabbit and anti-mouse fluorescent secondary antibodies were expressed as 1: 10000 dilution, incubation for 1h at room temperature, and washing the membrane on a shaking table for 3 times, 5min each time according to 5mL TBST of each strip after the incubation is finished; 9) exposure: and (3) sweeping the membrane by an Odyssey instrument to detect the change condition of the target protein.
Test example 3.1: the compounds of the invention induce WEE1 degradation in the MV-4-11 cell line.
The compounds of the invention were tested for cytotoxic IC using the WEE1 inhibitor AZD1775 as a positive control50The cells were treated in MV-4-11 cell line at a concentration for 6 hours, and cell lysates were collected and subjected to Western blotting analysis. As shown in figure 1, the levels of WEE1 protein after the effect of compounds 1-24 of the present invention were significantly reduced compared to compound AZD1775, indicating that WEE1 protein was degraded. As a proteomic control, PLK1 protein was not degraded.
Test example 3.2: compound 2 induced WEE1 degradation in MV-4-11 cell line at different concentrations.
Compound 2 was treated in MV-4-11 cell line for 6 hours at concentrations ranging from 0.2nM to 100nM using the WEE1 inhibitor AZD1775 as a positive control, and cell lysates were collected and subjected to Western blotting analysis. As shown in figure 2, compound 2 started to decrease in the level of WEE1 protein at the concentration of 0.39nM, with a significant decrease in the level of WEE1 protein at the concentration of 50 nM. As a proteomic control, PLK1 protein was not degraded.
Test example 3.3: compound 2 induced WEE1 degradation in MV-4-11 cell line at different times.
Two groups were set, one group was the compound 2 at 50nM concentration on MV-4-11 cell line and set for 0.5 h-6 h for 7 gradients, and one group was the compound 2 at 3nM concentration on MV-4-11 cell line and set for 1 h-5 h for 5 gradients, and cell lysates were collected and subjected to Western blotting analysis. As shown in fig. 3, compound 2 significantly reduced the protein level of WEE1 after 0.5 hour at 50nM and WEE1 after 1 hour at 3 nM. As a proteomic control, PLK1 protein was not degraded.
It can be seen that the compounds of the present invention have excellent ability to selectively degrade WEE1 protein.
Test example 3.4: protein target binding competition assay
The MV-4-11 cell line was pretreated with CRBN inhibitors Iberdomide (CC-220) and Lenalidomide (Lenalidomide) 10uM, proteasome inhibitors Crafizomib (PR171) and Bortezomib (PS341)1uM for 2 hours in the control group, and then treated with compound 2 at a final concentration of 50nM for 3 hours, and total protein samples were collected for Western blotting analysis. As shown in fig. 4, compound 2, in the experimental group not pretreated with protein inhibitor, at a concentration of 50nM on MV-4-11 cell line, induced significant degradation of WEE1 protein and resulted in a corresponding down-regulation of downstream phosphorylated PCDC 2; after pretreatment with CRBN inhibitor, compound 2 was unable to induce WEE1 protein degradation at a concentration of 50nM on the MV-4-11 cell line; after proteasome inhibitor pretreatment, compound 2 was unable to induce WEE1 protein degradation at 50nM concentration on the MV-4-11 cell line. As a proteomic control, PLK1 protein was not degraded. Protein target competitive binding experiments prove that the compound 2 is formed by relying on a ternary complex of WEE1 protein-compound 2-CRBN protein and passing through CRL4CRBNE3 ubiquitin ligase recruits WEE1 protein and then degrades WEE1 protein by a proteasome degradation system.
Test example 4: compound 2 induced degradation of WEE1 protein but not of WEE1 expressed mRNA.
As shown in fig. 5, compound 2 did not exhibit down-regulation of WEE 1-expressed mRNA transcriptome levels after 1,3 and 6 hours of action at 50nM, and it can be seen that the compound of the present invention did not affect the expression level of WEE1 transcriptome mRNA levels, and in combination with the results of the decreased expression level of WEE1 protein levels observed in the previous immunoblot experiments, it can be confirmed that: the compounds of the invention down-regulate WEE1 protein expression rather than mRNA transcriptome levels by degrading post-translational protein levels.
Test example 5: MV-4-11 tumor cell line G1 cycle arrest was induced.
Cell cycle arrest experimental principle and experimental method: the PI method is a classical periodic detection method. PI is a nucleic acid dye that specifically binds to DNA. After PI staining, the fluorescence intensity of G2/M phase cells is generally 2 times that of G0/G1 phase cells, and 1-2 times that of S phase cells undergoing DNA replication. By flow method, the proportion of cells with different DNA fluorescence intensity in the whole cell population can be examined, thereby determining the distribution of different cell cycles. The specific experimental steps are as follows:
1) cell culture: planting cells in a six-well plate, wherein each well is 1 × 106, the cells are in a growth logarithmic phase, and after the cells are stabilized for 3-4h and treated by different compounds for corresponding time, collecting the cells for detection; 2) cell treatment: collecting cells in 2mL centrifuge tube, 1000rpm centrifugation for 5min, 1mL precooling PBS heavy suspension washing, carefully suction supernatant; 3) cell fixation: fully resuspending 300 μ L PBS, adding 700 μ L precooled absolute ethyl alcohol while shaking to a final concentration of 75%, slightly shaking to make the cells become single cells, standing at 4 ℃ and fixing overnight; 4) the overnight fixed cells were washed twice with pre-chilled PBS, centrifuged at 1000rpm for 10min and 1mL PBS was added. Moving the cells into a 1.5mL EP tube, and slightly blowing up the dispersed cells to avoid cell clustering; 5) adding 2 μ L RNase (working concentration 20 μ g/mL), digesting RNA, resuspending cells, and digesting in water bath at 37 deg.C for 15 min; 6) adding PI dye 5 μ L to final concentration of 10 μ g/mL, dyeing at 4 deg.C in dark for 30min, and performing up-flow detection within 1 h; 7) fully mixing the cells, filtering by a 200-mesh filter screen, and performing cell cycle by using a flow cytometer; 8) collecting and analyzing data; red fluorescence was detected by flow cytometry. Cellular DNA content analysis was performed using FlowJo software.
As shown in FIG. 6, as the drug concentration of Compound 2 increased, the concentration was set to 5 gradients of 12.5nM, 25nM, 50nM, 100nM and 200nM on MV-4-11 tumor cell line for 24 hours, which was seen to have a block at stage G1.
Test example 6: compound 2 induces apoptosis in the MV-4-11 tumor cell line.
The experimental steps are as follows: 1) inoculating cells in a 6-hole plate according to an experimental scheme, inoculating 50W cells in each hole, stabilizing for several hours, treating the cells with compounds with different concentrations after the cells return to a normal culture state, and collecting the cells after 48 hours; 2) when the end point of the experiment is reached, all the following steps need to be gentle and slow, so that false positive of the experiment is avoided. Cells were first harvested by centrifugation (1000rpm, 5min) and washed twice with PBS; 3) sucking 500 mu L of Binding Buffer soft and heavy suspension cell sample of the apoptosis detection kit; 4) then adding 5 mul of Annexin V-FITC reagent provided by the kit into each sample, gently mixing the sample and the cells uniformly, and dyeing for 15min in a dark place at room temperature; 5) then, adding 5 mul of PI (propidium iodide) dye solution provided by the kit into each sample, gently mixing the PI (propidium iodide) dye solution with the cells, and dyeing for 5min in a dark place at room temperature; 6) then, the cells were mixed well, and the cells were filtered with a 200-mesh filter, and the cells were examined on the machine, and the examination by flow cytometry 7) and the examination by flow cytometry were carried out within 1 hour (C6 flow cytometer, BD corporation): firstly, a living cell group is circled, then a single cell group is circled after adhesion is removed, then 30000 cells are collected from each sample, Annexin V-FITC fluorescence is detected by using an FL1 channel, and PI fluorescence is detected by using an FL3 channel; 8) after data collection, data analysis and processing was performed using Flowjo10 software.
As shown in FIG. 7, as the concentration of compound 2 was increased, the concentration was set to 5 gradients of 12.5nM, 25nM, 50nM, 100nM and 200nM, and the apoptosis was significantly increased with increasing concentration in MV-4-11 tumor cell lines for 48 hours, with approximately 20% of the cells undergoing apoptosis.
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Claims (10)

1. A compound represented by formula V, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof;
Y-L-MWEE1 (V)
wherein the content of the first and second substances,
MWEE1is a WEE1 binding moiety capable of binding to WEE1 protein kinase;
y is an E3 ubiquitin ligase ligand moiety; and
l is a linking group.
2. The compound of claim 1,
(i) y is a group shown as formula A;
Figure FDA0002412646790000011
wherein the content of the first and second substances,
z is selected from the group consisting of: c (═ O), C (R)a)2、N(Rb)；
V1、V2、V3And V4One is C and the others are each independently selected from the group consisting of: c (R)a) And N;
R3selected from the group consisting of: H. halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl;
Raeach independently selected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
Rbeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p1 is 0, 1, 2, or 3;
or Y is a group shown as formula B;
Figure FDA0002412646790000012
wherein the content of the first and second substances,
V1、V2、V3and V4One is C and the others are each independently selected from the group consisting of: c (R)a) And N;
V5and V7Each independently selected from the group consisting of: c (R)a) And N;
V6selected from the group consisting of: c (R)6) And N;
R6selected from the group consisting of: H. cyano, C1-C6 alkyl, C1-C6 haloalkyl;
Raeach independently selected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p1 ═ 0, 1, 2, or 3;
or Y is a group shown as formula C;
Figure FDA0002412646790000021
wherein the content of the first and second substances,
R4selected from the group consisting of: H. halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl; and
R5selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl;
and/or the presence of a gas in the gas,
(ii) l is a linking group as shown in formula D
-(ML)s- (D)；
Wherein the content of the first and second substances,
MLare structural units each independently selected from the group consisting of: -C (R)c)2-、-C(Rc)2-C(Rc)2-O-、-C(Rc)2-C(Rc)2-S-、-O-、-S-、-N(Rn)-、-C(＝O)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn)-、-N(Rn)C(＝O)N(Rn)-、-SO-、-SO2-, -CH ═ CH-, -C ≡ C-, -C3-C8 cycloalkyl-, -4-to 7-membered heterocyclyl-, -C6-C10 aryl-, -5-or 6-membered heteroaryl-; wherein said cycloalkyl, heterocyclyl, aryl and heteroaryl are unsubstituted or optionally substituted with one or more (preferably, 1, 2, or 3) substituents selected from the group consisting of: halogen, CN, C1-C6 alkyl, C1-C6 haloalkyl;
subscript s is an integer of 1-30; preferably, the subscript s is an integer of 3 to 25; more preferably, the subscript s is an integer of 3 to 20;
Rceach independently selected from the group consisting of: H. hydroxy, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C3-C5 cycloalkyl; and
Rneach independently selected from the group consisting of: H. C1-C4 alkyl, C1-C4 haloalkyl, C3-C5 cycloalkyl;
and/or the presence of a gas in the gas,
(iii)MWEE1as shown in formula E:
Figure FDA0002412646790000022
wherein the content of the first and second substances,
Cy1selected from the group consisting of: substituted or unsubstituted C6-C10 cycloalkyl, substituted or unsubstituted 5-to 10-membered heterocycloalkyl;
Cy2selected from the group consisting of: substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-to 10-membered heteroaryl (preferably, 5-or 6-membered heteroaryl);
Rbeach independently selected from the group consisting of: H. C1-C6 alkyl, C1-C6 haloalkyl;
Rdeach independently selected from the group consisting of: H. halogen, C1-C6 alkyl, C1-C6 haloalkyl; and
subscript p2 is 0, 1, 2, or 3;
R1selected from the group consisting of: substituted or unsubstituted C1-C6 alkanesA group (preferably, C1-C4 alkyl), a substituted or unsubstituted C1-C6 alkenyl group (preferably, C1-C4 alkenyl group), a substituted or unsubstituted C1-C6 alkynyl group (preferably, C1-C4 alkynyl group), a substituted or unsubstituted benzyl group;
R2selected from the group consisting of: H. halogen, substituted or unsubstituted C1-C6 alkyl (preferably, C1-C4 alkyl), substituted or unsubstituted C1-C6 alkoxy (preferably, C1-C4 alkoxy), substituted or unsubstituted C6-C10 aryl;
x is selected from the group consisting of: c (R)a) And N;
Raselected from the group consisting of: H. halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl;
unless otherwise specified, said substitution means that one or more (preferably, 1, 2, 3,4 or 5) hydrogens on the group are substituted with a substituent selected from the group consisting of: hydroxyl, halogen (preferably, F, Cl, Br), CN, C1-C6 alkyl, C1-C6 haloalkyl.
3. The compound of claim 1,
l is a linking group of formula D1:
-Q1-(C(Rc)2)n-W-(C(Rc)2)n-W-(C(Rc)2)m- (D1)
wherein the content of the first and second substances,
Q1selected from the group consisting of: none (absent), -O-, -S-, -CH ═ CH-, -C ≡ C-, -N (R ≡ C)n)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn) -and-N (R)n)C(＝O)N(Rn)-；
Each W is independently selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Each subscript n is independently 0, 1, 2, 3,4, 5, 6, 7, or 8;
subscript m is 0, 1, 2, 3,4, 5, or 6;
Rcand RnAs defined in formula D;
alternatively, L is a linking group as shown in formula D2:
-Q2-[C(Rc)2-C(Rc)2-O]v-(C(Rc)2)o-W-(C(Rc)2)m- (D2)
wherein the content of the first and second substances,
Q2selected from the group consisting of: -N (R)n)-、-N(Rn)C(＝O)-、-C(＝O)N(Rn) -and-N (R)n)C(＝O)N(Rn)-；
W is selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Subscript v is 0, 1, 2, 3,4, 5, 6, 7, 8, 9, or 10;
subscript m is 0, 1, 2, 3,4, 5, or 6;
subscript o is 1, 2, or 3;
Rcand RnAs defined in formula D;
alternatively, L is a linking group as shown in formula D3:
-Q3-(C(Rc)2)r1-Ar1-(C(Rc)2)r2-U-(C(Rc)2)n-W-(C(Rc)2)m- (D3)
wherein the content of the first and second substances,
Q3selected from the group consisting of: -N (R)n) -, -O-and-S-;
Ar1selected from the group consisting of: -C3-C8 cycloalkyl-, 4-to 7-membered heterocyclyl-, -C6-C10 aryl-, -5-or 6-membered heteroaryl-;
w is selected from the group consisting of: none (absent), -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
U is selected from the group consisting of: -N (R)n)C(＝O)-、-C(＝O)N(Rn)-；
Subscript n is 0, 1, 2, 3,4, 5, 6, 7, or 8;
subscript m is 0, 1, 2, 3,4, 5, or 6;
r1 and r2 are each independently 0, 1 or 2;
Rcand RnAs defined in formula D.
4. The compound of claim 1,
(i) y is a group as shown in formula A1, A2, A3 or A4;
Figure FDA0002412646790000041
in the formulae (III), (III) Z, R3As defined above;
or Y is a group shown as formula B1;
Figure FDA0002412646790000042
or Y is a group shown as formula C1 or C2;
Figure FDA0002412646790000043
in the formulae, R4As defined above;
and/or the presence of a gas in the gas,
(ii) l is a linking group of formula D1 a:
-Q1-(CH2)n-W-(CH2)n-W-(CH2)m- (D1a)
wherein Q is1Subscripts m, W and subscript n are as defined in formula D1;
alternatively, L is a linking group as shown in formula D2 a:
-Q2-[CH2-CH2-O]v-(CH2)2-W-(CH2)n- (D2a)
wherein Q is2Subscripts v, W and subscript n are as defined in formula D2;
alternatively, L is a linking group as shown in formula D3 a:
-Q3-(CH2)-Ph-(CH2)r2-U-(CH2)n-W-(CH2)m- (D3a)
wherein Ph is phenyl and subscript r2 is 0 or 1; and Q3U, subscript m, W, subscript n and as defined in formula D3;
and/or the presence of a gas in the gas,
(iii)MWEE1is a group represented by E1;
Figure FDA0002412646790000044
5. the compound of claim 1, wherein the compound is of formula I;
Figure FDA0002412646790000051
wherein R is1、R2Y and L are as defined for formula V.
6. The compound of claim 1,
the compound is shown as a formula III;
Figure FDA0002412646790000052
wherein subscript n is 1, 2, 3,4, 5, 6, 7, or 8;
or, the compound is shown as formula IV;
Figure FDA0002412646790000053
wherein subscript n is 1, 2, 3,4, 5, 6, 7, or 8.
7. The compound of claim 1, wherein said compound is selected from the group consisting of the compounds of table 1.
8. A composition comprising (i) a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; and (ii) a pharmaceutically acceptable carrier.
9. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a composition of claim 8, in the manufacture of a medicament for the treatment and/or prevention of a disease or condition mediated by the WEE1 protein.
10. A method for degrading WEE1 protein, comprising the steps of: contacting a subject with a compound of claim 1, thereby degrading WEE1 protein.
CN202010181416.3A 2020-03-16 2020-03-16 WEE1 protein degradation agent Pending CN113402520A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010181416.3A CN113402520A (en) 2020-03-16 2020-03-16 WEE1 protein degradation agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010181416.3A CN113402520A (en) 2020-03-16 2020-03-16 WEE1 protein degradation agent

Publications (1)

Publication Number Publication Date
CN113402520A true CN113402520A (en) 2021-09-17

Family

ID=77676259

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010181416.3A Pending CN113402520A (en) 2020-03-16 2020-03-16 WEE1 protein degradation agent

Country Status (1)

Country Link
CN (1) CN113402520A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268066A1 (en) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 Protein degradation agent
WO2023083194A1 (en) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1 protein kinase degradation agent and use thereof
WO2023125944A1 (en) * 2021-12-31 2023-07-06 正大天晴药业集团股份有限公司 Compound containing heterocyclic ring
WO2023138362A1 (en) * 2022-01-18 2023-07-27 江苏天士力帝益药业有限公司 Wee1 inhibitor, preparation therefor, and use thereof
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
WO2019201123A1 (en) * 2018-04-20 2019-10-24 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals
CN110372693A (en) * 2018-07-04 2019-10-25 清华大学 It is a kind of targeting degradation BET albumen compound and its application
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN110835345A (en) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 Degradation agent of cell cycle dependent kinase, preparation method thereof, pharmaceutical composition and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
WO2019201123A1 (en) * 2018-04-20 2019-10-24 四川科伦博泰生物医药股份有限公司 Multifunctional compound, preparation method therefor, and application thereof in pharmaceuticals
CN110372693A (en) * 2018-07-04 2019-10-25 清华大学 It is a kind of targeting degradation BET albumen compound and its application
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN110835345A (en) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 Degradation agent of cell cycle dependent kinase, preparation method thereof, pharmaceutical composition and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZHENGNIAN LI等: "Development and Characterization of a Wee1 Kinase Degrader", 《CELL CHEMICAL BIOLOGY》 *
王瑞峰等: "蛋白降解靶向嵌合体( PROTAC) 的研究进展", 《中国药物化学杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268066A1 (en) * 2021-06-22 2022-12-29 苏州开拓药业股份有限公司 Protein degradation agent
WO2023083194A1 (en) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1 protein kinase degradation agent and use thereof
WO2023125944A1 (en) * 2021-12-31 2023-07-06 正大天晴药业集团股份有限公司 Compound containing heterocyclic ring
WO2023138362A1 (en) * 2022-01-18 2023-07-27 江苏天士力帝益药业有限公司 Wee1 inhibitor, preparation therefor, and use thereof
WO2023193789A1 (en) * 2022-04-08 2023-10-12 Beijing Neox Biotech Limited Wee1 degrading compounds

Similar Documents

Publication Publication Date Title
CN113402520A (en) WEE1 protein degradation agent
CN113999226B (en) Heterocyclic compounds as KRAS inhibitors and methods of use thereof
CN106459009B (en) Hepatitis C virus inhibitor and its pharmaceutical applications
CN103038233B (en) Pyridone and azepine pyridinone compounds and application method
CN113087700A (en) Spirocyclic tetrahydroquinazolines
CN106817900A (en) Novel naphthyridines and isoquinolin and its purposes as CDK8/19 inhibitor
CN109311864A (en) The pyridine and application method that heteroaryl replaces
WO2022135470A1 (en) Preparation and application method of heterocyclic compound as kras inhibitor
WO2020011246A1 (en) Benzene ring-containing compound, preparation method therefor and application thereof
CN101959882A (en) Imidazole carbonyl compound
CN103619817A (en) Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators
CN113784963A (en) Compounds useful as RET kinase inhibitors and uses thereof
TW201348213A (en) Quinazolinedione derivative
CN108947985A (en) Compound and its preparation method and application as autophagy regulator
JP2019526577A (en) Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancer
CN104136399A (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN115335373A (en) Compound and use thereof
WO2022268230A1 (en) Compound as kif18a inhibitor
CN108440507B (en) Compound as apoptosis protein inhibitor and application thereof
CN113045569B (en) Compounds useful as RET kinase inhibitors and uses thereof
CN114685488A (en) Compounds as SOS1 inhibitors and uses thereof
CN108570038B (en) Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and application thereof
JP7299350B2 (en) Bicyclic compounds and their use as RIP-1 kinase inhibitors
CN110028508B (en) Antitumor diazo bicyclic apoptosis protein inhibitor
JP4681526B2 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210917